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ABSTRACT 
 
DANIEL W. BELSKY: Informing Public Health Approaches to Obesity and Smoking  
Using Genome-Wide Association Studies:  
Genetic Epidemiology Affirms the Importance of Early Prevention 
(Under the Direction of Joseph P. Morrissey and Avshalom Caspi) 
 
Rapid advances in technology and scientific methods stimulated by the sequencing of 
the human genome have yielded discoveries that begin to uncover the genetic roots of common 
chronic health conditions.  However, the implications of these discoveries for public health 
research and practice remain unclear. Three questions are central to building a translational 
pipeline that links genetic discovery research with interventions to improve health: First, when 
in the life course do genetic risks become manifest?  Second, what are the magnitudes of risks 
that can be predicted using genetic information? And third, do genetic markers provide new 
information about risk over and above the existing technology of family health history 
assessment?  This dissertation research seeks to address these questions for two prevalent and 
costly sources of morbidity and early mortality, obesity and smoking. Results reveal that (1) 
genetic risks manifest early in the development of obesity and smoking through processes that 
may be amenable to public health intervention; (2) the magnitudes of risk that can be predicted 
using genetic information are small; but (3) the risk information provided by genetic markers is 
independent of information available in a family history. These findings affirm recommendations 
of caution in the application of genetic information to predict health risks in individuals, but 
suggest promise as more powerful but less common genetic risks are discovered in the 
continuing evolution of genomic research. Further, these findings recommend an increased 
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focus on childhood and adolescence in genetic discovery research and add a genetic rationale to 
arguments for early intervention to prevent obesity and smoking.  
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CHAPTER 1.  
INTRODUCTION 
 
Rapid advances in technology and scientific methods driven by the human genome 
project have yielded discoveries about the genetic roots of common chronic health conditions.
1
  
However, the implications of these discoveries for public health research and practice remain 
unclear.
2
 The major engine for genetic discovery in the genomic era has been the genome-wide 
association study (GWAS). GWAS measure millions of common variants, called single-nucleotide 
polymorphisms
a
 (SNPs), to capture the full range of common variation in the genome. The 
GWAS “experiment” uses large samples of individuals, often assembled in a case-control design, 
to test associations between each of these millions of SNPs and a trait or health outcome. The 
GWAS asks, for each SNP, is the distribution of alleles different in affected cases as compared to 
unaffected controls? This theory-free data mining approach to genetic discovery allows GWAS 
to leapfrog current biology.
3
 However, the large number of tests (one for each SNP) requires a 
stringent statistical correction, with the result that GWAS require extremely large samples to 
discover all but the most powerful genetic risk factors.
4
 These large samples are typically 
assembled, at least in part, from clinical populations. Therefore, follow-up of GWAS discoveries 
in epidemiologically-sound cohorts is needed to characterize the public health implications of 
genetic risks.
5
 Such characterization is a critical link in the translational pipeline between genetic 
discovery research and interventions to improve public health.
6
 Three questions are central to 
characterizing GWAS-discovered genetic risks: First, when in the life course do genetic risks 
become manifest? Second, what are the magnitudes of risks that can be predicted using genetic 
                                                          
a
 The genome is composed of nucleotide chains. Each nucleotide is represented with a letter in the human 
genetic code. A single nucleotide polymorphism is a single-letter substitution in this code, e.g. from 
adenine (‘A’) to guanine (‘G’) or from cytosine (‘C’) to tyrosine (‘T’), that occurs in at least 1% of the 
population.  
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information? and Third, do genetic markers provide new information about risk over and above 
the existing technology of family health history assessment?  
The program of research described in the three empirical studies that comprise this 
dissertation seeks to characterize the public health implications of GWAS-discovered genetic 
risks for two prevalent and costly sources of morbidity and early mortality, obesity and smoking. 
I use theory-free GWAS to derive multi-locus profiles of genetic risk for obesity and smoking, 
called “genetic risk scores” (GRSs). I validate these GRSs using data from a large, population-
based cohort of older adults (n=15,792). I then leverage the power of a complete birth cohort 
(n=1,037) followed through their fourth decade of life to investigate how genetic risk indexed in 
the GRSs influences the development of obesity and smoking problems across the first half of 
the life course. Results reveal that (1) GRSs can be used to investigate GWAS-discovered genetic 
risks for obesity and smoking in population-based cohorts much smaller than the original GWAS 
discovery samples; (2) genetic risks identified in GWAS manifest early in the development of 
obesity and smoking through processes that may be amenable to public health intervention; (3) 
the magnitudes of risk that can be predicted using genetic information are small; but (4) the risk 
information provided by genetic markers is independent of information available in a family 
history. These findings affirm recommendations of caution in the application of genetic 
information to predict health risks in individuals,
7-9
 but suggest promise as more powerful but 
less common genetic risks are discovered in the continuing evolution of genomic research. 
Further, findings recommend an increased focus on childhood and adolescence in genetic 
discovery research and add a genetic rationale to arguments for early intervention to prevent 
obesity and smoking.
10, 11
  
The remainder of this introduction presents (I) The logic for investing GWAS discovered 
genetic risks in public health research; (II) The methods to be used in this investigation; and (III) 
The three empirical chapters that follow. 
I. Logic for Investigating GWAS-Discovered Genetic Risks in Public health Research  
(A) Genetic variation is an important determinant of individual differences in morbidity and 
mortality. Studies of twins and families indicate that relatives who share more of their genetic 
code also share liability to many common chronic health conditions.
12
 Family studies estimate 
that as much as 80% of population variation in body mass index and 50% of population variation 
3 
 
in smoking behavior may be attributed to genetics.
13, 14
 Recent genetic discoveries appear to 
explain small fractions of population variance in obesity and smoking.
15
 However, these 
discoveries provide a critical window into how genetic risk operates and, through interactions 
with other genetic or environmental factors, may account for a larger share of variation in 
morbidity than initial estimates suggest.
16, 17
 Therefore, this research seeks to understand how 
discovered genetic risks influence the development of obesity and smoking in the population to 
inform the development of hypotheses about how genetic risk factors with apparently small 
effects may give rise to large differences in health outcomes.  
 (B) Genetic information can reveal health risks in time to prevent disease. DNA sequence 
variants remain constant across the life course; sequence variants that predict health risk in 
adulthood can be measured accurately from birth to assess risk in pre-symptomatic 
individuals.
18
 Many complex conditions are sensitive to risk exposures early in life and to 
patterns of health behavior that develop during childhood. This is true of obesity and smoking;
19, 
20
 and, although evidence-based preventative interventions are available to mitigate early-life 
risks, poor uptake and adherence pose enduring challenges.
21-25
 In addition to improving 
identification of persons at risk, there is evidence that genetic risk information, if communicated 
effectively in clinical settings, may help to motivate behavior change.
26, 27
 This research attempts 
to lay a foundation that could ultimately target public health interventions to the most 
vulnerable “windows” in the development of these health problems. 
Genotyping costs are declining rapidly (more than 100,000 fold in the past decade)
28
 and 
personal genomes are making their way to clinicians and, through direct to consumer services, 
to individuals with no formal medical training.
29
 Research is therefore needed to understand the 
effectiveness of genome-based risk assessments for complex health conditions.
30-32
 Ultimately, 
the effectiveness of genetic risk assessments must be evaluated in terms of their clinical utility—
can the results of genetic screens change provider behavior in ways that improve patient 
health?
33
 Before clinical utility can be tested, it is necessary to first generate hypotheses about 
how genetic information can be effectively deployed.
2
 To generate such hypotheses, 
information is needed about when in the development of a health condition genetic risk 
becomes manifest, what the magnitudes of that risk are, and whether risk information furnished 
by genetic markers can also be obtained using the existing technology of family history 
assessment.
32
 The research undertaken in this dissertation seeks to inform the development of 
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hypotheses about how genetic information can be deployed to prevent obesity and nicotine 
dependence.   
II. Methods for Investigating GWAS-Discovered Genetic Risks in Public health Research 
 (A) The first step in translating discoveries from the frontiers of genome science into tools 
that can improve public health is to follow-up discoveries in longitudinal population-based 
cohort studies. GWAS scan the entire genome for correlations between measures of health and 
genetic variants, usually single base-pair changes in the human DNA sequence that occur in >1% 
of the population, called “single nucleotide polymorphisms” (SNPs). GWAS analyses comprise 
large numbers of statistical tests, one for each SNP measured—a few hundred thousand in early 
versions, upwards of 2 million in the most recent studies.
4
 To minimize the risk of detecting false 
positive signals, GWAS apply a stringent statistical correction.
b
 The field standard significance 
threshold is p<1x10E-8. At this threshold, only large effects can be detected in standard 
epidemiological samples.
34
 One of the first discoveries of the genomic age was that few SNPs 
have such large effects.
35
 To address the challenge posed in detecting small effects while 
maintaining the 5% type-1 error rate of conventional epidemiological studies, researchers 
assembled ever-larger samples.
36
 In the case of most complex health conditions, samples of tens 
of thousands of individuals are needed.
37
 These large samples can be effective for discovery 
research, but follow-up in epidemiologically sound population-based cohorts followed over time 
is needed to characterize the implications of genetic discoveries for population health.
38
  
Population-representative samples are necessary to address selection issues inherent in the 
case-control designs of many GWAS samples and the recruitment of subjects from clinical 
populations.
39
 Without resolving such issues, it is unclear how genetic risk effects estimated in 
GWAS translate to the general population.
40
 This is a particular problem for obesity and 
smoking, which are subject to complex environmental influences
41, 42
 and are the target of much 
clinical and public health attention.
43
 This makes the clinical populations that constitute 
significant portions of GWAS samples problematic for interpreting genetic effects. Therefore, 
this dissertation uses the population-based Atherosclerosis Risk in the Communities (ARIC) 
cohort
44
 to validate genetic risk measurements.  
                                                          
b
 The statistical correction applied in GWAS is a modified version of the Bonferroni correction, which takes 
the alpha level (acceptable type-1 error rate) and exponentiates it to the power of the number of tests 
conducted. In GWAS, the Bonferroni correction is adjusted to account for correlation or “linkage” 
between SNPs.  
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Longitudinal data including repeated measurements of health states are necessary to 
address questions of when in the development of a health problem genetic risks become 
manifest. Questions of when genetic risks becomes manifest are of critical importance for public 
health practice as intervention to disrupt genetic risk is likely to be most effective before the 
onset or early in the development of processes that entrain later health problems. Early stages 
in the development of adult obesity and smoking problems are critical to pathogenesis: 
Individual differences in obesity risk emerge during gestation and are further established during 
infancy and childhood through accelerated growth trajectories.
45, 46
 Etiological research on 
smoking highlights the progression from initiation to heavy use during adolescence as a key 
marker of risk for subsequent dependence.
47, 48
 Therefore, this dissertation uses the Dunedin 
Multidisciplinary Health and Development Study (Dunedin Study) cohort, a complete birth 
cohort followed over 4 decades with nearly complete retention, to investigate how GWAS-
discovered genetic risks for obesity and smoking manifest during development.  
(B) Aggregating risk variants discovered in GWAS to create “genetic risk scores” can facilitate 
investigations of genetic risk in databases with rich longitudinal data to describe the 
developmental course of a health condition. Prospective longitudinal cohort studies containing 
repeated measures of health states at multiple points in the life course are necessary to 
elucidate developmental processes leading to complex diseases.
39
 A challenge for research 
following-up GWAS discoveries in such population-based cohorts is that effect sizes for the 
individual alleles that are the units of analysis in GWAS are small. In the case of the two 
conditions examined in this dissertation, obesity and smoking, the most highly penetrant (i.e. 
most pathogenic) alleles predict at most a half a point increase in adult body-mass index (BMI) 
or a single cigarette per day increase in tobacco consumption among smokers.
49, 50
 A related 
challenge is that GWAS-identified SNPs do not measure genetic risks with precision.
51
 GWAS 
measure only 100,000 – 2 million of the ~15 million SNPs in the human genome. GWAS methods 
assume that these SNPs capture the full range of common genomic variation because SNPs that 
are close together on the genome are non-independent, a phenomenon known as linkage 
disequilibrium (LD).
52
 Two SNPs are said to be in LD when they are inherited together (when 
their co-occurrence in a population departs significantly from the expectation given their 
individual frequencies). When LD is strong, SNPs co-occur with sufficient frequency that each 
SNP serves as a proxy for the other SNP.
53
 Proxy SNPs are adequate to test associations in 
samples of tens of thousands. However, in more modest samples, the imprecision or “noise” 
6 
 
that results from imperfect correlation between a proxy SNP and the causal variant that 
contributes directly to disease etiology can overwhelm the “signal” and result in failure to detect 
the association.   
Many longitudinal studies with data necessary to investigate the development of complex 
health conditions are underpowered to test the effects of individual SNPs identified in GWAS.
54
 
However, there is evidence that many GWAS-identified SNPs contribute additively to disease 
risk,
55-58
 and this is particularly true in the case of obesity and smoking.
59-62
 If genetic 
contributions to risk are additive, it is possible to sum risk alleles across GWAS-identified SNPs to 
compute a “genetic risk score” (GRS).
63, 64
 The resulting GRS provides a valid index of the 
continuum of genetic risk in the population.
65
 Because GRSs measure the aggregate effect of a 
number of SNPs, they can be used to test associations in the smaller samples that have 
adequate data to investigate genetic influence over developmental processes. Therefore, as an 
initial step, this dissertation research uses GWAS discoveries to derive GRSs for obesity and 
smoking and then uses the GRSs to investigate genetic risk for obesity and smoking.   
III. Three Empirical Chapters 
(A) The first empirical chapter, Development and Evaluation of a Genetic Risk Score for Obesity, 
describes how results from 16 GWAS of obesity and related phenotypes were used to derive the 
obesity GRS. The chapter then presents an analysis of the predictive validity of the GRS for adult 
obesity among European- and African-descent populations in the ARIC cohort.  
(B) The second empirical chapter, Polygenic Risk for Adult Obesity is Mediated by Rapid 
Childhood Growth, uses the GRS derived in the first chapter to investigate when genetic risk for 
obesity manifests in development. This chapter also describes analyses to test whether the 
obesity GRS provides different information about risk from a family history assessment. This 
chapter is currently in-press at the Archives of Pediatrics & Adolescent Medicine. 
(C) The third empirical chapter, Polygenic Risk Accelerates the Developmental Progression of 
Smoking Behavior from Initiation to Heavy, Persistent Use and Nicotine Dependence, uses 3 
meta-analyses of GWAS of smoking quantity (cigarettes smoked per-day by individuals who 
have ever smoked) to derive a GRS for smoking. It then uses this GRS to investigate how genetic 
risk for smoking relates to developmental and clinical phenotypes of smoking behavior. This 
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chapter also describes analyses to test whether the smoking GRS provides additional 
information about risk with that derived simply from a family history assessment. 
 
  
 
 
 
CHAPTER 2.  
DEVELOPMENT AND EVALUATION OF A GENETIC RISK SCORE FOR OBESITY 
INTRODUCTION 
Genome-wide associations study (GWAS) results represent a potentially rich source of 
information for etiological and treatment research that builds bridges between genome science 
and clinical and public health practice. 
66, 67
 Given the large number of such studies, sufficient 
GWAS data exist to support such translational research for a number of common chronic health 
conditions, including obesity 
3, 68
. Infrastructure is in place at the start of the translational 
pipeline with GWAS data banked and curated in continuously updated searchable databases. 
3, 69
 
Likewise, at the other end of the pipeline, evidence from translational research is evaluated to 
establish the clinical utility of genomic information and to issue guidelines for clinical practice. 
6
 
However, significant gaps remain in the middle of the translational pipeline and approaches are 
needed to support research at this juncture, where population-based samples with rich 
environmental and phenotypic measurements can be used to follow-up disease markers 
identified in GWAS. Specifically, systematic approaches are needed to sift the results of 
numerous association studies and distill the most promising set of markers for further 
investigation. These approaches must be able to harness the power of existing resources and to 
flexibly accommodate new data produced by the fast pace of discovery in genome science.  
A key hurdle for research using GWAS results is that risk SNPs identified in GWAS may 
not cause adverse health outcomes, but may instead be proxies for (correlated with) 
unmeasured disease-causing variation in the genome.
70, 71
 GWAS methods exploit LD across the 
genome to leverage measurement of 100,000 – 1 million SNPs to capture variation in the 10 
million plus SNPs the genome is estimated to contain. The very large sample sizes in GWAS 
permit detection of risk associations even when proxy SNPs are in imperfect LD with disease-
causing variation (correlation<1). GWAS findings are generally applied to smaller samples 
designed to elucidate etiological and clinical correlates of discovered genes. When GWAS SNPs 
 9 
 
are translated to research using smaller samples, the measurement error resulting from 
imperfect LD with disease causing variants can attenuate associations below levels these 
samples are powered to detect. Genetic risk scores (GRSs) summarize risk-associated variation 
across the genome
63
 by aggregating information from multiple risk SNPs (the simplest GRSs 
count disease-associated alleles). Because GRSs pool information from multiple SNPs, each 
individual SNP is less important to the summary measurement and the “signal” from the GRS is 
robust to imperfect linkage for any one SNP. For the same reason, GRSs are less sensitive to 
minor allele frequencies for individual SNPs. As the number of SNPs included in a GRS grows, the 
distribution of values approaches normality, even when individual risk alleles are relatively 
uncommon.
72
 Therefore, the GRS can be an efficient and effective means of constructing 
genome-wide risk measurements from GWAS findings. 
Obesity is a public health problem that is well suited to risk assessment using a GRS. It is 
highly prevalent;
73
 it is a significant source of health-care costs, morbidity, and mortality;
74-76
 it is 
under strong genetic influence; 
13
 and GWAS are beginning to elucidate its molecular genetic 
roots.
77
 Therefore, translational research in obesity genomics may ultimately help to address a 
public health priority. A key challenge is that obesity’s genetic roots are diffuse, multifactorial, 
and non-deterministic; many variants scattered across the genome each contribute small risks 
for obesity.
78
 In other words, information from multiple genetic variants is needed to 
characterize genetic susceptibility to obesity. Thus, a GRS may be useful. A further challenge is 
uncertainty about the specific genetic variants to be included in an obesity GRS. Different GWAS 
identify different genomic loci and, when loci are replicated across GWAS, the specific SNPs 
identified may be different.
79
 To address this challenge, we developed a 3-stage approach to 
review GWAS results and select specific SNPs to include in a GRS. We devised our approach to 
be systematic and replicable and to leverage the discovery potential of GWAS while minimizing 
risk for including false-positive markers. In this article, we describe this 3-stage approach, apply 
it to develop a GRS for obesity, and test the GRS as a measure of obesity risk using data from the 
population-based Atherosclerosis Risk in the Communities (ARIC) Study.  
METHODS 
Sample. The ARIC sample is described elsewhere.
44, 80
 Briefly, ARIC is a prospective 
epidemiologic cohort study sponsored by the National Heart, Lung, and Blood Institute to 
investigate the etiology of atherosclerotic disease. The study draws from 4 US communities: 
 10 
 
Minneapolis MN, Washington County MD, Forsyth County, NC, and Jackson MS. Participants 
were examined first during 1987-1989, and at 3 subsequent occasions (1990-1992, 1993-1995, 
and 1996-1998), with ongoing follow-up conducted annually by telephone. ARIC cohort 
genotype data from the Affymetrix Affy 6.0 Chip and selected phenotypes were obtained for this 
study from the NIH dbGaP.  
The original ARIC sample includes 15,792 participants (27% African American, 55% 
female). The publicly available dataset obtained from dbGaP for this study includes genotype 
and phenotype data for 12,771 individuals. Of this sample, 1,212 participants had a missing call 
rate >2% for SNPs called successfully in ≥95% of the sample and were excluded from subsequent 
analyses per quality control recommendations of the GENEVA ARIC Project.
81
 In addition, 
although the ARIC study design did not aim to include relatives, genomic analysis by the ARIC 
investigators revealed familial relationships at the level of half-siblings or closer among 1,674 
participants. One member was selected at random from each of the 105 “families” to form a 
sample of unrelated persons. After these exclusions, the sample consisted of 10,745 participants 
(23% African American, 55% female, hereafter the “analysis sample”).  
Body Mass Index and Obesity. Body mass index (BMI: kg/m
2
) was calculated from 
measurements of weight to the nearest pound and height to the nearest centimeter. Obesity 
was defined according to U.S. Centers for Disease Control and Prevention Criteria as BMI≥30. 
Anthropometric measurements were collected from participants wearing a scrub suit and no 
shoes at the 4 in-person data collections.  
Genotypes. Details on the genotyping of the ARIC sample are available through dbGaP 
and are described elsewhere.
82
 Briefly, genotyping was conducted by the Broad Institute using 
the Affymetrix Affy 6.0 SNP array and the Birdseed calling algorithm.
83
 Following guidelines for 
the use of genotypic data provided by the ARIC GWAS team, data were extracted for all SNPs 
with a sample-wide call rate ≥95%, fewer than 5 discordant calls across duplicated DNA samples 
in the quality control subsample (n=334), and in Hardy-Weinberg Equilibrium (p>0.001).  
Genetic Risk Scores. Current mid-pipeline translational studies use either a “best guess” 
approach or a “top hits” approach to select genetic markers to include in GRSs. The “best guess” 
approach selects markers identified in association studies that are located in or near genes with 
plausible biological relationships to the pathophysiology of a phenotype or that demonstrate 
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strong and replicable association signals.
84-86
 The “top hits” approach selects markers with the 
strongest association signals in a single GWAS, independent of their biological plausibility.
87, 88
 
Early studies have illustrated the promise of translational research with GWAS markers, but as 
the field moves forward, more systematic approaches are needed that can better integrate new 
information from the latest studies. Neither the top-hits nor the best-guess approach provides a 
systematic and replicable means of integrating results from multiple GWAS. Meta-analysis can 
accomplish this, but comprehensive meta-analyses are not always available. Moreover, the top-
hits and best-guess approaches do not provide a means to select specific SNPs for follow-up, 
and this problem is not solved by meta-analysis. The approach of selecting the “lead” SNP at a 
locus, usually the SNP with the lowest p-value in the largest GWAS, is problematic because 
different GWAS can report different lead SNPs for the same locus because of differences in 
GWAS chips, genotyping quality, and data handling and analysis decisions. Thus, an approach is 
needed that facilitates systematic and replicable SNP selection from results of multiple GWAS.  
Our 3-stage approach integrates public-access resources including continuously updated 
databases of GWAS results, web-based whole-genome analysis tools, and  genome-wide data to 
identify the most promising set of single nucleotide polymorphisms (SNPs) for follow-up. Most 
importantly, the 3-stage approach addresses key limitations of the top-hits and best-guess 
approaches: It provides a systematic and replicable means of integrating findings across multiple 
GWAS and of selecting SNPs for follow-up in new samples.  The 3 stages are:  
Stage 1) Extraction: All SNPs associated with one of the selected phenotypes at a given 
significance threshold are “extracted” from each GWAS and retained for further analysis.  
Stage 2) Clustering: Extracted SNPs are “clustered” according to patterns of linkage 
disquelibrium (LD) determined from a reference population that matches the population in the 
GWAS included in Stage 1. Clustering yields a set of “LD blocks.”  
Stage 3) Selection: Statistical significance and replication are evaluated at the level of 
the LD block. The original GWAS results are used to assign a minimum p-value and a replication 
count for each LD block. The minimum p-value is the lowest p-value reported for any SNP in the 
LD block in any GWAS contributing data in Stage 1. The replication count is the number of GWAS 
that reported an association for any SNP in the LD block at the threshold defined in Stage 1.  
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We applied our 3-stage approach to construct two GRSs for obesity. First, we considered 
only GWAS published in print or online through December 31, 2008. We chose these GWAS 
because they were used in previous research that created “top-hits” and “best-guess” obesity 
GRSs. Thus, we used these GWAS to construct a GRS using our 3-stage approach and compared 
it to two published GRSs.
61, 62
 Second, we considered all GWAS published through December 31, 
2010. We applied our 3-stage approach to results from the full set of GWAS and compared the 
resulting GRS to a top-hits GRS generated from the largest meta-analysis of BMI GWAS 
published to date
89
 and to a best-guess GRS generated from the full set of obesity-associated 
SNPs reported in the National Human Genome Research Institute (NHGRI) GWAS Catalog.
79
 The 
derivation of the GRS using the 3-stage approach is described in detail in the supplemental 
material (Appendix A). Analyses described in the supplemental material revealed that the 3-
stage approach created GRSs that were at least as predictive of BMI and obesity as GRSs created 
with the top-hits and best-guess approaches. Further analyses to refine the 3-stage approach 
GRS yielded a final set of 32 SNPs (see Appendix A). We applied 2 weighting schemes to the 32 
SNPs before summing them to create our obesity GRS: 1) equal weighting, under which the 
score was a simple count of BMI-increasing alleles; and 2) effect-size weighting, under which 
BMI-increasing alleles were weighted by the effect size reported for that locus in the GIANT 
Consortium 
89
 or DeCode 
90
 BMI GWAS. Effect-size weights were adjusted for LD between the 
SNP tested in the GWAS and the SNP genotyped in the ARIC sample. Each of the 32 SNPs in the 
GRS was missing for fewer than 1% of participants in any gender/ethnicity cell. GRSs were 
prorated by dividing the GRS by the number of SNPs contributing data and multiplying by 32. 
The SNPs included in the final obesity GRS, their BMI-increasing (“effect”) alleles, nearby genes, 
and weights are reported in Table 2.1.  
Evaluation of the Obesity GRS. Associations between the GRS and obesity-related traits 
(BMI, weight, waist circumference, obesity) were tested with linear and logistic regression 
models. These and subsequent models were adjusted for demographic and geographic control 
variables: age was specified as a linear and a quadratic term; a product term was included for 
the interaction between age and sex to account for sex differences in BMI and obesity 
distributions at different ages; the 4 ARIC Study Centers where participants were enrolled in the 
study were entered as a series of dummy variables (this collection of variables is referred to 
hereafter and elsewhere in the manuscript as demographics and geography). Predictiveness of 
the GRS was evaluated using 3 metrics that are established tools for evaluating risk markers in 
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general 
91
 as well as for the specific case of genetic risk scores:
92
 1) R
2
, the proportion of 
variation explained in BMI.  R
2
 was estimated using demographics and geography-adjusted 
linear regression models. 2) AUC, the area under the receiver operating characteristic curve for 
obesity, also known as the discrimination index. The AUC corresponds to the probability that a 
randomly selected obese case will have a higher GRS as compared to a randomly selected non-
obese control. A marker that discriminates no better than chance has an AUC of 0.50. A marker 
that discriminates perfectly has an AUC of 1. A related metric is the partial AUC (PAUC). The 
PAUC sets a specificity threshold and calculates an AUC-like statistic specific to that specificity. 
Analyses of PAUC for the GRS set specificity at 80% (the bottom 5
th
 of the ROC curve). AUC and 
PAUC analyses were stratified by ARIC Study Center using Pepe’s method.
93
 To determine 
whether the GRS improved discrimination over and above demographic and geographic 
information, we calculated a second set of statistics, delta AUC and delta PAUC. Probit 
regression models were used to generate predicted probabilities of obesity for each ARIC 
participant using a baseline model that included demographic and geographic information and a 
test model that also included the GRS. AUCs and were calculated using these predicted 
probabilities as “risk scores,” 
94
 and estimates of the differences between the baseline and test 
models were bootstrapped to obtain confidence intervals. AUC analyses were conducted using 
the Stata package “comproc. 
95
 3) IDI, the integrated discrimination index for obesity. The IDI 
evaluates the added predictiveness of a marker by comparing predictions made using a baseline 
set of risk markers to predictions that also include information about the new risk marker:  
IDI=(Probtest, obese – Probtest,non-obese)  – (Probbaseline, obese – Probbaseline, non-obese) 
where “Prob” is the average predicted probability for a particular group from a particular model. 
The IDI measures change in model sensitivity net of change in model specificity and is a more 
sensitive measure than delta AUC.
96
 An IDI of zero indicates that the test model performs 
comparably to the baseline model. Positive IDI values index net improvement in model 
sensitivity. Baseline and test models for IDI analyses were identical to those used in delta AUC 
analyses.  
We tested differences between the predictiveness metrics for different risk scores by 
bootstrapping confidence intervals around the R
2
 and AUC metrics (comparing the difference in 
estimated metric values across 1,000 random samples drawn with replacement from the ARIC 
database
95
) and by applying Pencina’s method 
96
 to test change in the IDI metric. Comparisons 
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were as follows: Un-Weighted GRS vs. Weighted GRS; Weighted GRS vs. Simple Genetic Risk 
Assessment (the sum of risk alleles at the two best-replicated obesity loci, in the gene FTO and 
downstream of the gene MC4R, rs9939609 and rs12970134, respectively); Weighted GRS vs. 
Socioeconomic Index (Educational attainment measured in 5 categories: grade-school or less, 
some high school, high school graduate, vocational school, college, graduate/professional 
school, Appendix A, Supplementary Table 2.8). 
RESULTS 
Obesity risk-allele distributions were similar for males and females, but were different 
for whites and African Americans. The variance of the un-weighted GRS was greater for whites 
as compared to African Americans (SD= 3.50 as compared to 3.25, p<0.001 using Brown and 
Forsythe’s method 
97
), as was the mean (M=28.80 as compared to 24.87, p<0.001 using t-test for 
unequal variances; see also Appendix A, Supplementary Figure 2.1). This difference reflected 
lower frequencies of BMI-increasing alleles for several GRS SNPs among African American ARIC 
participants (Table 2.1). Subsequent analyses were stratified by race. 
The obesity GRSs were weakly but consistently associated with BMI and the probability 
of being obese among whites and African Americans, but associations were weaker among 
African Americans (Figure 2.1). Among whites, after adjusting for age, sex, and geography, the 
un-weighted GRS was associated with BMI at r=0.12 and the weighted GRS was associated with 
BMI at r=0.13 (p<1x10
-26 
for both). This effect size corresponded to a 0.60-unit increase in BMI 
per 1-standard-deviation increase in the GRS. For each 1-standard-deviation increase in their un-
weighted and weighted GRSs, a white ARIC participant’s risk for obesity increased by 19.35% 
and 20.51%, respectively (p<1x10
-18
 for both). Among African Americans, the weighted and un-
weighted GRSs were associated with BMI at r=0.05 (p<0.05  for both). For each standard 
deviation increase in their un-weighted and weighted GRSs, an African American ARIC 
participant’s risk for obesity increased by 3.54% (p=0.059) and 4.92% (p=0.017), respectively. 
Results were substantively unchanged when control variables were removed from the models. 
We conducted a series of additional sensitivity analyses to evaluate heterogeneity in GRS 
associations (described in detail in Appendix A). These analyses supported a linear association 
between the GRS and BMI; showed that GRS-BMI associations were similar to GRS-weight and 
GRS-waist circumference associations; and revealed no sex or age differences in GRS-BMI 
associations. 
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The obesity GRSs performed similarly on the 3 predictiveness metrics (Table 2.2). The 
top panel of Table 2 addresses clinical validity. It presents the 3 metrics for the un-weighted and 
weighted GRSs. Among whites, weighted and un-weighted obesity GRSs explained small, but 
statistically significant proportions of the variance in BMI (R
2
), discriminated obese from non-
obese participants modestly better than chance (AUC), and contributed small net improvements 
to the sensitivity of an obesity prediction model over and above demographic and geographic 
information (IDI). Among African Americans, the GRS did not contribute to the explanation of 
variance in BMI over and above demographic and geographic information, to the discrimination 
of obese from non-obese participants, or to the net sensitivity of the obesity prediction model. 
Use of weights derived from BMI GWAS improved the performance of the GRS among whites 
and African Americans, but this improvement was not statistically significant (p>0.10 for all 
comparisons).  
The bottom panel of Table 2 addresses research utility. It presents predictiveness 
metrics for two comparison measures of obesity risk: the simple genetic risk assessment 
(weighted combinations of rs9939609 in FTO and rs12970134 downstream of MC4R) and the 
socioeconomic index (a 5-category measure of educational attainment). The FTO and MC4R loci 
and socioeconomic status are robust correlates of BMI and obesity in adult samples.
98, 99
 
Comparison of the 32-locus GRS to a two-locus risk assessment can illustrate whether the GRS 
offers value added over a simpler genetic risk assessment. Comparison of the GRS to 
socioeconomic status can illustrate how the predictiveness of the GRS compares to the 
predictiveness of a social determinant of obesity that is not easily changed but that is 
understood to be important in etiological research.
100
 Among whites, the genetic risk scores 
performed better than the comparison measures of obesity risk on all 3 metrics (p<0.01 for all 
comparisons). Among African Americans, the GRSs performed no differently from the simple 
genetic risk assessment (p>0.10) and performed less well as compared to the socioeconomic 
index (p=0.021). When combined with the comparison risk measures and with demographic and 
geographic information, the GRS improved predictiveness for whites but not for African 
Americans (Appendix A, Supplementary Table 2.9). 
Figure 2 shows the model-based receiver operating characteristic curves for a baseline 
model that included demographic and geographic information and a test model that also 
included the weighted GRS. The change in AUC from the baseline model to the test model was 
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greater than zero (Delta AUC=0.048, 95% CI 0.313-0.658, p<10
-7
), indicating that the GRS 
improved discrimination of obese cases. This improvement in discrimination was concentrated 
at low specificities, but extended to the portion of the ROC curve of greatest interest to 
clinicians. At a specificity of 0.8, the test model including the GRS was marginally more sensitive 
as compared to the baseline model (Delta Partial AUC=0.007, 95% CI <0.0003-0.010, p=<0.001). 
Results for African Americans are presented in Supplementary Figure 2.2 (Appendix A).    
As a final analysis, we asked whether the obesity GRS was associated with mortality risk. 
The ARIC study conducted follow-up with participants through December 31, 2004 to determine 
whether study members had died. Mortality follow-up data were available for 8,284 of the 
8,286 white participants in our analysis sample. 15% of this sample (n=1,253 individuals) died 
during the 17 years of follow-up from the first study visit. We analyzed mortality risk using Cox 
proportional hazard models to adjust for demographic and geographic factors. Independent of 
demographics and geography, individuals with higher genetic risk scores were more likely to die 
during the follow up period (Hazard Ratio=1.12, 95% CI [1.04-1.15]). Consistent with analyses of 
BMI and obesity, the GRS was not associated with mortality among African Americans. Figure 
2.3 presents cumulative mortality hazards for white ARIC participants in the top, middle, and 
bottom quintiles of the genetic risk distribution. The mortality hazard associated with the GRS 
did not depend on individuals’ BMIs. Adjustment of the mortality hazard model for BMI only 
slightly reduced the mortality hazard associated with genetic risk (Hazard Ratio=1.10 [1.04-
1.17]).  
 
DISCUSSION 
 We used a 3-stage approach to construct an obesity GRS from GWAS results. Our tests 
of this obesity GRS in the population-based ARIC cohort revealed it to be a highly statistically 
significant predictor of BMI measured at 4 time points across 10 years, of weight and waist-
circumference, and of obesity. In terms of value added, the GRS improved prediction of BMI and 
obesity over and above demographic and geographic information, FTO and MC4R genotypes, 
and information about socioeconomic status. Thus, the GRS provides a measure of genetic 
predisposition to obesity that could inform etiological and treatment research. Finally, the GRS 
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was associated with mortality risk. Interestingly, higher mortality risk for individuals with higher 
GRSs did not depend on their BMI.  
The research utility of the GRS is likely limited to samples of European descent. GRS-BMI 
and GRS-obesity associations in African American ARIC participants were much smaller than 
comparable associations in white ARIC participants. Although the sample included fewer African 
Americans than whites, power to detect effects of equal size to those observed in whites was 
well over 80% in the African American sample. Moreover, effect-size measures (r, R
2
, relative 
risk, AUC, IDI) showed little evidence that the GRS predicted BMI or obesity among African 
Americans. These results suggest caution in using GWAS of European-descent populations to 
derive GRSs for African Americans. Our analyses indicated the GRS performed similarly among 
men and women. However, emerging evidence for gene-sex interactions in obesity 
101, 102
 
suggests that future obesity GRSs may require sex-specific construction. 
 Our results have implications for theory, research, and clinical practice. With respect to 
theory, our results are consistent with the hypothesis that genetic risk for obesity is 
quantitatively distributed and can be operationalized in a GRS.
65
 With respect to research 
methods, our findings illustrate one approach to operationalize quantitative genetic risk. A 
systematic and replicable approach to selecting SNPs from association studies to follow-up in 
etiological and treatment research will be especially important with the advent of next-
generation sequencing approaches. Next generation sequencing is likely to uncover many new 
disease-associated loci for obesity and for other phenotypes of interest to clinicians and 
researchers. These variants, though rarer in the population, may have higher penetrance and 
thus greater clinical relevance. Future research can also make use of the GRS derived in this 
study as a measure of inherited obesity risk. With respect to clinical practice, results indicate 
that, for persons in middle age, GWAS SNP-based approaches to obesity risk assessment offer 
little in the absence of more detailed information about lifestyle and environment. Although 
genetic information reliably predicted risk for obesity over and above demographics and 
geography, the magnitude of this additional risk was insufficient to recommend our score for 
use in clinical risk assessments. This result is especially important in the context of questions 
over consumer genomics services.
103
 Our 3-stage approach derived a more comprehensive 
genetic risk assessment for obesity than those currently used by companies marketing genomics 
services directly to consumers. The very modest risk information furnished by our GRS 
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recommends caution on the part of consumers and health professionals in interpreting risk 
information provided by consumer genomics companies. The standard of evidence used here—
multi-method assessment of predictiveness in large, population-based samples--should be 
considered a minimum standard for the validity of such risk information.   
These results should be considered in light of the following limitations: First, some ARIC 
participants were included in the samples of some of the GWAS used to construct the GRS. 
However, these ARIC participants represented a minority of the GWAS samples and results in 
the ARIC sample are similar to results from samples not included in any of the GWAS.
61, 62
 
Second, some risk loci identified by our 3-stage approach could be genotyped in the ARIC 
sample using only relatively weak proxies. Given the small improvement to predictiveness 
associated with each additional SNP included in the GRS, it is unlikely that this limitation 
influenced the substance of our results, but it is possible that our GRS is moderately more 
predictive than analyses in the ARIC cohort suggest. Third, our analyses were limited to African 
American and white Americans. The ARIC cohort does not contain Asian-descent or Hispanic 
individuals. It remains unclear whether the relatively greater similarity between these and 
European populations 
104
 would support the generalization of our GRS. However, GWAS of Asian 
and Hispanic samples 
88, 105
 suggest that a European-descent population-derived GRS may omit 
important risk loci for these populations. As more GWAS of non-European populations become 
available, our 3-stage approach can be used to derive additional population-specific GRSs. 
Fourth, there is mounting evidence that many genetic factors predisposing individuals to obesity 
are sex specific 
106
 and that GWAS that fail to model such sex specificity may not detect 
important risk variants.
107
 Results from GWAS modeling gene-by-sex interaction support this 
hypothesis.
101, 102, 108
 As more such GWAS become available, our 3-stage approach can be used to 
derive sex-specific GRSs for obesity. Finally, the ARIC sample is limited to individuals in middle 
age. There is evidence that genetic risk for obesity has dynamic consequences across 
development.
109, 110
 It will be important in subsequent investigations to evaluate our obesity GRS 
in longitudinal cohorts that capture a broader section of the life course, and particularly in 
young people, as they are a key prevention target.
10
  
 We constructed a GRS for obesity and showed that it predicted BMI and obesity in a 
population-based sample of middle-aged adults. We further showed that this GRS was 
longitudinally associated with mortality risk. These associations suggest that future research into 
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obesity etiology and treatment can make use of genetic information. However, our analyses do 
not support the use of genetic testing for individual-level obesity-risk prediction. Future 
research with this GRS should characterize the expression of genetic risk across the life course 
and particularly during childhood, when intervention to prevent the development of obesity 
may be most effective.    
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Table 2.1. Single nucleotide polymorphisms included in the obesity genetic risk score (GRS). 
Alleles are reported from the forward strand. The GRS was computed by counting the number of 
effect alleles at each SNP, multiplying that number by the SNP’s weight, and then summing the 
results across the set of 32 SNPs. Weights reflect per-allele changes in BMI estimated in the the 
GIANT Consortium GWAS meta-analysis 
89
 except for rs867559, for which the weight was 
estimated in the DeCODE GWAS meta-analysis 
90
. 
 
  
Whites African Americans 
NEGR1 rs2815752 G A 0.13 62% 55%
TNNI3K rs1514175 A G 0.07 43% 68%
PTBP2 rs1555543 A C 0.06 58% 43%
SEC16B rs543874 G A 0.22 20% 25%
FANCL rs759250 A G 0.10 29% 8%
LRP1B rs2121279 T C 0.08 14% 3%
TMEM18 rs2867123 G C 0.30 83% 88%
RBJ rs10182181 G A 0.14 54% 16%
CADM2 rs12714640 A C 0.10 19% 6%
ETV5/DGKG rs1516728 T A 0.11 77% 48%
GNPDA2 rs12641981 T C 0.18 43% 23%
SLC39A8 rs13114738 T C 0.13 8% 1%
POC5 FLJ35779 rs10057967 C T 0.10 63% 51%
ZNF608 rs6864049 A G 0.07 54% 81%
6 TFAP2B rs734597 A G 0.13 17% 9%
LING02 LRRN6C rs1412235 C G 0.11 31% 16%
LMX1B rs867559 G A 0.24 20% 32%
RPL27A rs2028882 C A 0.06 50% 34%
BDNF rs10501087 C T 0.18 79% 93%
MTCH2 rs12419692 A C 0.05 36% 9%
12 BDCDIN3D, FAIM2 rs7138803 A G 0.12 38% 17%
13 MTIF3, GRF3A rs1475219 C T 0.09 21% 22%
PRKD1 rs1440983 A G 0.15 5% 23%
NRXN3 rs7144011 T G 0.13 22% 24%
15 MAP2K5 rs28670272 G A 0.13 77% 59%
GPR5B rs11639988 G A 0.17 85% 76%
ATXN2L, TUFM, SH2B1 rs12443881 T C 0.15 39% 9%
FTO rs9939609 A T 0.38 41% 48%
18 MC4R rs12970134 A G 0.21 26% 13%
KCTD15 rs11084753 A G 0.04 67% 64%
QPCTL rs11083779 C T 0.07 96% 89%
ZC3H4 TMEM160 rs7250850 G C 0.09 71% 20%
16
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Effect Alle Frequency (ARIC Sample)
Chr Nearby Gene SNP
Effect 
Allele
3
4
5
9
11
14
1
2
Other 
Allele Weight
  
 
Table 2.2. Predictiveness Metrics for the 3-Stage Approach Obesity Genetic Risk Score and Comparison Measures of Risk for Obesity. 
The simple genetic risk score is a component of the weighted obesity genetic risk scores. Values of R
2
 were estimated using linear 
regression models and reflect the improvement in the proportion of variance explained by the model beyond the baseline prediction 
derived from demographic and geographic information. Percentile-based confidence intervals (CIs) were generated using the bootstrap 
method. Areas Under the Curve (AUCs) and CIs were estimated from ROC curves constructed for raw values (i.e. actual values of the 
measures tested rather than predicted values generated from a regression model) and were adjusted for the ARIC Study Center where 
data were collected. Integrated Discrimination Indexes (IDIs) and test statistics were estimated for comparisons of a baseline model 
including demographic and geographic information to a test model that included this information and the GRS.  
R
2
 (95% CI) AUC (95% CI) IDI (p-value) R
2
 (95% CI) AUC (95% CI) IDI (p-value)
1.39% 0.565 0.009 %0.11 0.515 0.001
(0.94% - 1.89%) (0.550 - 0.581) (4.65E-18) (-%0.04 - %0.57) (0.491 - 0.540) (0.067)
1.57% 0.570 0.010 %0.14 0.521 0.002
(1.11% - 2.10%) (0.554 - 0.584) (8.25E-20) (-%0.03 - %0.65) (0.497 - 0.544) (0.152)
0.59% 0.543 0.004 -%0.02 0.516 0.001
(0.31% - 0.97%) (0.528 - 0.557) (3.54E-09) (-%0.04 - %0.25) (0.493 - 0.539) (0.149)
0.57% 0.532 0.003 %1.06 0.561 0.016
(0.29% - 0.87%) (0.517 - 0.546) (7.83E-07) (%0.42 - %1.99) (0.538 - 0.584) (2.71E-11)
Simple Genetic Risk Assessment 3.88% 0.550 5.35% 0.607
Weighted GRS 4.88% 0.574 5.52% 0.609
1.00% 0.024 0.006 0.17% 0.002 0.001
(0.58%-1.42%) (0.012-0.036) (7.81E-13) (-%0.15-%0.51) (-0.005-0.009) (0.055)
Socioeconomic Status 4.70% 0.550 7.70% 0.643
Socioeconomic Status + weighted GRS 6.20% 0.586 7.92% 0.645
1.50% 0.036 0.010 0.22% 0.002 0.002
(1.00%-1.99%) (0.023-0.050) (5.46E-19) (-%0.14-%0.55) (-0.003-0.008) (0.012)
Weighted GRS 
Change in predictiveness with addition 
of weighted GRS to model
Panel C. Predictiveness of model-based risk assessments (including demographic and geographic information)
Socioeconomic Index: 5-category measure 
of educational attainment
Change in predictiveness with addition 
of weighted GRS to model
Simple Genetic Risk Assessment:                             
FTO & MC4R-linked SNPs only
White ARIC Participants (n=8,286)
Un-Weighted GRS 
Panel B. Predictiveness of comparison risk measures 
Black ARIC Participants (n=2,442)
Panel A. Predictivness of the un-weighted and weighted obesity GRSs
2
1
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Figure 2.1 Panel A. BMI for White and African American ARIC Participants Plotted Against the 
Weighted Obesity Genetic Risk Score. Dashed outlines represent 95% confidence intervals. 
Pearson correlations (r) were adjusted for gender, age and ARIC Study Center where data were 
collected. Removal of outliers (not shown) did not alter correlation estimates at the third 
decimal point. Correlations were statistically significant for white (p<1x10
-30
) and African 
American (p=0.014) ARIC participants. 
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Figure 2.1 Panel B. Percentage White and African American ARIC Participants Who Were 
Obese (BMI≥30kg/m
2
) at the First Study Visit, by Quintile of Genetic Risk Score. Quintiles were 
determined separately for whites and African Americans. Error bars represent 95% confidence 
intervals. Risk ratios are for comparisons of highest to lowest quintiles of genomic risk and were 
estimated with adjustment for gender, age, and ARIC study center where data were collected. 
Dashed lines represent sample means. Among white ARIC participants, all quintile to quintile 
differences are statistically significant (p<0.01), with the exception of the 3
rd
 and 4
th
 quintiles. 
Among African American ARIC participants, the percent obese in the lowest quintile was lower 
than in the third and fourth quintiles (p<0.05).   
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Figure 2.2. Receiver Operating Characteristic Curves for Obesity Among White ARIC 
Participants (n=8,286). Baseline Model = gender, age (quadratic), gender x age interaction, ARIC 
study center; Test Model = baseline model + weighted obesity genetic risk score. ROC curves 
were constructed using predicted values from probit regressions of obesity (BMI≥30) on the 
model terms. Delta AUC (AUCTest-AUCBaseline) = 0.048, 95% CI 0.031-0.066, p<1x10
-7
. Delta Partial 
AUC at 80% specificity=0.007, 95% CI 0.003-0.010, p<0.001. AUCs, partial AUCs, and delta AUCs 
were estimated using Pepe’s method 
93, 95
.   
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Figure 2.3. Cumulative Mortality Hazards for White ARIC Participants in the Highest, Middle, 
and Lowest Genetic Risk Score (GRS) Qunitiles. Hazards were estimated from a Cox 
proportional hazard model adjusted for age, sex, the age-sex interaction, and the ARIC Study 
Center where data were collected. The dashed line represents sample-wide mortality at the end 
of follow-up (15%). By the end of follow-up, unadjusted mortality was 12.17% in the lowest GRS 
quintile, 15.48% in the middle GRS quintile, and 17.32% in the highest GRS quintile.  
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CHAPTER 3. 
POLYGENIC RISK FOR ADULT OBESITY IS MEDIATED BY  
RAPID CHILDHOOD GROWTH: 
EVIDENCE FROM A 4-DECADE LONGITUDINAL STUDY
3
 
 
INTRODUCTION 
 
Obesity is known to be heritable and genome-wide association studies (GWAS) have begun 
to uncover the molecular roots of this “heritability” by identifying multiple single-nucleotide 
polymorphisms (SNPs) associated with higher adult body mass index (BMI).
78
 The next step is to 
understand how these SNPs influence the development of obesity. Individual differences in 
obesity risk emerge during gestation and are further established during infancy and childhood 
through accelerated growth trajectories.
46, 132
 Therefore, examination of developmental 
phenotypes in relation to genetic risk represents a promising approach to understand the 
pathogenesis of obesity.
109, 110, 133
 In this study, we asked how SNPs with replicated GWAS 
evidence for association with adult BMI relate to growth across the first four decades of life and 
to adult obesity in a birth cohort followed prospectively from birth through age 38 years.  
SNPs identified in GWAS contribute small increments to obesity risk.
49
 Aggregating GWAS-
identified SNPs to produce a genome-wide index (a “genetic risk score”) yields a quantitative 
measure of inherited predisposition towards a trait, such as BMI.
65
 This approach has shown 
promise in the study of complex diseases such as diabetes and heart disease.
55, 56
 In this study, 
we used a multi-locus genetic-risk score to test how a genetic predisposition to higher adult BMI 
might also relate to developmental phenotypes of growth during proposed critical periods in the 
development of obesity. Three developmental phenotypes are of interest: Growth during 
gestation, postnatal growth, and the adiposity rebound. All correlate with adult BMI and are 
thought to program risk for adult obesity.
10, 134, 135
 Therefore, we tested the hypothesis that 
polygenic risk for adult obesity is mediated by these developmental phenotypes of rapid early 
                                                          
3
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AK Biddle, JA Blumenthal, JP Evans, HL Harrington, K Sugden, B Williams, R Poulton, and A Caspi 
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growth (Figure 1). Understanding when in development genetic risk for obesity is expressed can 
help to refine research and intervention targets.  
If genetic risk is mediated through early growth, it would be important to know how 
measured genetic risk compares to parental BMI in predicting children’s growth and obesity risk. 
We thus tested whether obesity risk information contained in the genetic risk score was 
independent of obesity risk information contained in the BMIs of children’s parents. That is, 
does the genetic risk score contain novel information about children’s risk for obesity over and 
above their family history? 
METHODS 
 
PARTICIPANTS 
Participants are members of the Dunedin Multidisciplinary Health and Development 
Study, a longitudinal investigation of health and behavior in a complete birth cohort. Study 
members (N=1,037; 91% of eligible births; 52% male) were all individuals born between April 
1972 and March 1973 in Dunedin, New Zealand, who were eligible for the longitudinal study 
based on residence in the province and who participated in the first follow-up assessment at age 
3. The cohort represents the full range of socioeconomic status in the general population of 
New Zealand’s South Island and is primarily white. Assessments were carried out at birth and at 
ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, and, most recently, 38 years, with over 90% retention.  
At each assessment, study members are brought to the Dunedin research unit for a full day of 
interviews and examinations. The Otago Ethics Committee approved each phase of the study. 
Informed consent was obtained from all study members. 
 
MAIN EXPOSURES 
Obesity Genetic Risk Score. We derived a 32-SNP genetic risk score (GRS) from 
published genome-wide association studies (GWAS) of body mass index (BMI), obesity, weight, 
and waist circumference in European-descent populations. The construction of the GRS is 
described in the Appendix B. We validated our GRS as a measure of obesity risk in data from the 
Atherosclerosis Risk in the Communities (ARIC) sample.
81
 European-descent individuals in the 
ARIC sample with higher GRSs were larger as measured by BMI, weight, and waist circumference 
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(r>0.10, p<1x10
-20
), and were more likely to be obese (Relative Risk (RR)=1.73, 95% CI 1.51-1.97 
for individuals in the highest vs. the lowest quintile of the GRS distribution).  
We genotyped the 32 GRS SNPs in the Dunedin Study cohort with the Illumina BeadPlex 
Array using DNA extracted from whole blood (93% of the sample) or buccal swabs (7% of the 
sample). Of the 32 GRS SNPs, 29 were called successfully in >95% of the cohort and we 
constructed the final score from these SNPs (Appendix B, Supplemental Table 3.1). Comparison 
of the 29-SNP GRS to the original 32-SNP GRS in the ARIC sample revealed no differences in 
score distribution or effect sizes. Dunedin Study members carried between 15 and 36 risk alleles 
(Mean (M)=26.04, Standard Deviation (SD)=3.32). After weighting, GRS values ranged from 
13.71-35.04, M=24.71, SD=3.59 (Appendix B, Supplemental Figure 3.1). The GRS was 
standardized to have a mean of 0 and a standard deviation of 1 for analyses.  
Family History of Obesity. Parent BMI was available for 98% of the cohort. Parents’ 
BMIs were computed from self-reports of height and weight when children were aged 11 years. 
To measure familial predisposition to obesity, BMIs of parents were standardized within sex and 
the standardized scores were averaged to create a single family-history score.  
 
OUTCOME MEASURES 
BMI. Individuals’ height and weight were measured at ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 
32, and 38 years. Height was measured to the nearest millimeter using a portable Harpenden 
Stadiometer (Holtain, Crymych, UK). Weight was recorded to the nearest 0.1kg using a Lindell 
Beam Balance at ages 3, 5, 7, 9, 11, 13, 15, and 21 years and calibrated scales at ages 26, 32, and 
38 years. Individuals were weighed in light clothing. BMI was computed as weight (kg)/height 
(m
2
). Obesity was  defined at age 15 using U.S. Centers for Disease Control and Prevention cut 
points (BMI≥24.64 for boys, BMI≥25.46 for girls), which show similar predictive validity for 
obesity and coronary heart disease in young adulthood to International Obesity Task Force cut 
points.
136
 Obesity was defined at ages 18-38 years as BMI≥30. Individuals who met obesity 
criteria at ≥50% of 6 measurements between 15 and 38 years were classified as chronically 
obese.
137
 
Additional Measures of Adiposity. At ages 7 and 9 years, tricep and subscapular skinfold 
thicknesses were measured by trained anthropometrists. At ages 26, 32, and 38 years, waist 
 29 
 
girth was measured by averaging two measurements of the perimeter at the level of the 
noticeable waist narrowing. At ages 32 and 38 years, fat mass was measured using the Tanita 
Body Composition Analyzer BC1418 to assess bioelectrical impedence.
138
  
Developmental Phenotypes of Early Growth. Rate of early-childhood weight gain was 
assessed as the difference between weight at birth (from hospital records) and weight at age 3 
years. Adiposity rebound was calculated as the nadir of each individual’s childhood BMI curve 
fitted over ages 3-13 years. We used multilevel longitudinal modeling to fit individual growth 
curves.
139
 Models included linear and quadratic slope terms and were adjusted for sex.  Children 
in our sample experienced adiposity rebound around age 6 years (M=6.11 years, SD=1.10 years) 
at a BMI around 16 (M=15.57, SD=1.00).  
 
ANALYSES 
We analyzed life-course growth using a multilevel longitudinal growth model
139
 fitted to BMI 
measurements at ages 3, 5, 7, 9, 11, 13, 15, 18, 32, and 38 years. We set the intercept at age 13 
years. We modeled separate linear and quadratic slopes for growth during childhood (ages 3-13 
years) and adulthood (ages 13-38 years). The intercept captured the sample mean BMI at age 13 
years (β=19.97). Slope coefficients captured annual change/acceleration in BMI. Linear slope 
terms captured change in BMI across childhood (β=1.19) and adulthood (β=0.51). Quadratic 
slope terms captured acceleration of change--the concavity of the trajectory in childhood 
(β=0.08) and the convexity of the trajectory in adulthood (β=-0.01). All model parameters were 
statistically significant (p<0.001).   
We tested genetic influence on growth by modeling the intercept and linear slope 
parameters of the life-course growth curve as functions of the GRS and covariates. GRS 
coefficients measured the effect of a one standard deviation increase in genetic risk on BMI at 
age 13 years (intercept) and on the linear change per-year in BMI between ages 3 and 13 years 
(childhood slope) and ages 13 and 38 years (adulthood slope).  
We tested genetic associations with cross-sectional measurements of BMI and with other 
quantitative traits using linear regression models. GRS coefficients were standardized to effect-
size correlations (Pearson’s r) for ease of interpretation. We tested genetic associations with 
obesity risk using Poisson regression models. GRS coefficients were exponentiated to compute 
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relative risks (RR). We tested mediation of genetic risk for obesity through developmental 
phenotypes of early growth  using the structural equation described by MacKinnon & Dwyer.
140
 
Mediation analyses decomposed GRS-obesity associations into direct (un-mediated) and indirect 
(mediated through a developmental phenotype) components. Statistical tests of mediation were 
conducted using methods described by Preacher and colleagues.
141-143
 
All models were adjusted for sex and comprised the 98% (n=856) of European-descent 
Dunedin Study members with available body mass index, family history, and genotype data.  We 
used SAS 9.2
144
 for growth modeling and mediation analyses and Stata 11.0
145
 for other 
analyses. 
 
 
RESULTS 
 
Children with higher genetic risk scores (GRSs) were larger and grew faster during 
childhood and during adulthood. Children with higher GRSs had higher BMIs at every age 
assessed, from age 3 to 38 years (Table 3.1). In the life-course growth model, higher GRSs 
predicted higher mean levels of BMI (intercept β=0.38, p<0.001), faster growth in childhood 
(β=0.03, p<0.001) and faster growth in adulthood (β=0.02, p=0.017). Figure 3.2 shows life-
course growth curves for children with high, low, and average GRSs.  
To rule out the possibility that variation at the FTO locus accounted for our observed GRS-
growth associations, we repeated the analysis, adjusting slope and intercept estimates for the 
FTO SNP rs9939609, which is the best replicated GWAS result for BMI,
79
 has been shown to 
influence growth,
98, 109
 and carried the largest weight of any SNP in our GRS. GRS-growth 
associations were unchanged by adjustment for rs9939609. Independent of their rs9939609 
genotype, children with higher GRSs were larger across four decades of follow-up (intercept 
β=0.40, p<0.001) and grew faster during childhood and during adulthood (childhood linear slope 
β=0.03, p=0.003; adult linear slope β=0.02, p=0.013).  
To rule out the possibility that GRS-growth associations reflected associations with height or 
with muscle mass and not with adiposity, we tested associations between the GRS and 
childhood skinfold thicknesses and adult waist-girth and fat-mass measurements. These 
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measurements are less susceptible to inflation as a result of body-size and are considered to be 
more direct measures of body fat.
138
 GRS correlations with these alternative measures of 
adiposity were statistically significant and were similar to GRS correlations with BMI (Table 1). 
Children with higher genetic risk scores were at greater risk for obesity across two 
decades of adult follow-up. As teenagers (ages 15-18 years), 6% of Dunedin Study children had 
BMIs in the obese range; in their 20s, 11% met criteria for obesity; by age 38 years, 23% met 
criteria for obesity, consistent with nationwide prevalence among European-descent New 
Zealanders (http://socialreport.msd.govt.nz/health/obesity.html). 9% of the sample were 
classified as chronically obese. Figure 3.3 shows obesity prevalences for children at low (below 
average) and high (above average) genetic risk. Children at high genetic risk were between 1.61- 
and 2.41-times more likely to be obese in their teens, 20s, and 30s, and were 1.90-times likely to 
be chronically obese across 3+ assessments as compared to children at low genetic risk.  
Polygenic risk for adult obesity is mediated by developmental phenotypes of rapid 
childhood growth. To determine whether genetic risk for obesity was mediated through rapid 
early growth, we investigated relationships among children’s GRSs, their growth during 
gestation and childhood, and their obesity outcomes across two decades of adult follow-up.   
The first developmental period theorized to entrain adult obesity risk is gestation. However, 
the GRS was not associated with fetal growth as indexed by birthweight (r=0.00, p>0.90, Table 
1).  Nevertheless, by age 3 years, children at higher genetic risk had higher BMIs relative to their 
peers (r=0.08, p=0.043), raising the question of whether growth between birth and age 3 years 
mediated genetic risk for obesity. Children at higher genetic risk did gain more weight between 
birth and age 3 years (r=0.09, p=0.014, Table 3.1). Consistent with previous research,
146, 147
 
children with more rapid birth-3 weight gain were more likely to become obese (Table 3.2). 
Decomposition of GRS-obesity associations into direct effects and indirect effects indicated that 
birth-3 weight-gain mediated statistically significant portions of genetic risk for obesity in the 
teens and for chronic obesity, but not for obesity in the 20s or 30s individually (Table 3.2).  
Adiposity rebound, when children begin to gain body fat after losing it during early 
childhood, is a third period in development theorized to entrain adult obesity. For children at 
higher genetic risk, adiposity rebound occurred earlier in development and at higher BMI (r=-
0.13 for age and r=0.17 for BMI, p<0.001 for both, Table 3.1). Consistent with previous 
research,
134, 148
 children with earlier adiposity rebound and higher BMI at adiposity rebound 
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were more likely to become obese (Table 3.2). Decomposition of GRS-obesity associations into 
direct effects and indirect effects revealed that adiposity rebound mediated large and 
statistically significant portions of genetic risk for obesity in the teens, 20s, and 30s and for 
chronic obesity (Table 3.2). 
The genetic risk score contained information about children’s growth and their risk for 
obesity in adulthood that was not available in their family histories. Higher genetic risk 
predicted faster growth and increased risk for obesity in children with normal-weight parents 
and in children with overweight parents (Figure 3.4 Panels A and B). That is, the GRS 
contributed independent and additive information to the prediction of children’s growth and 
their risk for obesity in adulthood over and above family history information (Appendix B, 
Supplementary Table 3.2).  
 
DISCUSSION 
 
We conducted a developmental genetic investigation into the etiology of obesity in a four-
decade long prospective birth-cohort study. We measured polygenic risk for obesity using a 
multi-locus genetic risk score derived from GWAS of obesity-related phenotypes. Our analyses 
revealed that polygenic risk for obesity was partly mediated by rapid growth in the early 
childhood years following birth. This finding supported our hypothesis that developmental 
phenotypes were critical in linking a genetic predisposition to adult obesity. Furthermore, risk 
for obesity measured by the genetic risk score was independent of risk information available in 
parental BMI.  
These findings have implications for clinical practice and for developmental and 
epidemiologic research. First, the results suggest promise for utilizing genetic information in 
obesity risk assessments. Parent BMI has been proposed as a screening measure to target 
obesity prevention in children on the basis of effect-size correlations only slightly larger than 
those we report for our genetic risk score.
149
 New developments in genome science, including 
next-generation sequencing, may uncover new variants that further improve the performance 
of a SNP-based risk assessment.
150-152
 Moreover, the genetic risk score contained information 
about children’s future obesity risk that could not be derived from measurements of parents, 
suggesting that positive family history may not always be an appropriate prerequisite for genetic 
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testing. Second, our findings illustrate how polygenic influences on development can be 
investigated using genetic risk scores. Prospective-cohort studies containing repeated measures 
are necessary to elucidate developmental processes leading to complex diseases.
39
 But to date, 
small single-locus effect sizes have made it challenging to incorporate genetic information into 
ongoing cohort studies. To address the challenge of small effects, we used a multi-locus profile.  
The resulting genetic risk score enables measurement of a larger, genome-wide effect size and 
reduces the number of hypothesis tests to one, making follow-up of GWAS findings tractable in 
cohort studies that are needed to study development. Third, the longitudinal results illustrate 
that investigations of obesity as an outcome to developmental processes can inform public 
health initiatives and research priorities by identifying specific phases in development when 
genetic risk becomes manifest and thus might be amenable to intervention. Childhood growth in 
general, and in particular growth during the period between birth and the adiposity rebound, 
should be a focus for future research to understand genetic contributions to the development of 
obesity.  
We acknowledge three limitations. First, we derived our genetic risk score from GWAS of 
Europeans and conducted our study in European-descent individuals; these results may not 
generalize to other populations.
5
 Second, our family histories included only parents. It is 
possible more complete family histories have greater overlap with the genetic risk score. Third, 
we were unable to characterize growth trajectories during the earliest stages of life; regular 
follow-up of the cohort did not begin until age 3 years. However, results from our analyses of 
birthweight and of birth-3 weight gain were consistent with previous genetic investigations of 
this interval that did include repeated measurements.
109, 110, 153, 154
 Moreover, we were able to 
capture growth from age 3 years onwards with a high degree of resolution; our study included 
12 measurements taken over the subsequent 35 years. In addition to repeated measures of 
height and weight, our study included more direct measures of adiposity, including childhood 
measurements of skinfold thicknesses and adult measurements of waist circumference and fat 
mass, all of which were associated with our genetic risk score in parallel to BMI. Thus, the results 
present compelling evidence that SNPs identified in GWAS of adult BMI and other obesity-
related phenotypes predispose to more rapid growth in childhood, leading to increased risk for 
obesity in adulthood, and provide information not forthcoming from a simple analysis of family 
history. 
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Table 3.1. Descriptive Statistics and Correlations with Genetic Risk Score and Family History 
Score for Anthropometric Assessments Among Individuals of European Descent (n=856). All 
correlations were adjusted for sex. Tests of statistical significance were conducted using 
heteroskedasticity robust standard errors. *** p<0.001, **p<0.01, *p<0.05. 
Measure / Age at Measurement Mean SD
Body Mass Index (kg/m
2
)
3 16.33 (1.28) 0.08 * 0.11 **
5 15.88 (1.18) 0.13 *** 0.19 ***
7 15.82 (1.29) 0.17 *** 0.24 ***
9 16.33 (1.62) 0.18 *** 0.21 ***
11 17.49 (2.09) 0.16 *** 0.22 ***
13 19.59 (2.47) 0.18 *** 0.23 ***
15 20.37 (2.60) 0.17 *** 0.30 ***
18 22.73 (3.02) 0.15 *** 0.31 ***
21 23.74 (3.41) 0.18 *** 0.31 ***
26 24.89 (4.27) 0.16 *** 0.29 ***
32 26.03 (4.80) 0.13 *** 0.31 ***
38 26.92 (5.13) 0.14 *** 0.34 ***
Alternative Measures of Adiposity
Subcapular Skinfold Thickness (mm)
7 5.87 (1.92) 0.07 ** 0.12 **
9 6.67 (2.80) 0.11 *** 0.10 **
Tricep Skinfold Thickness (mm)
7 8.46 (2.46) 0.07 * 0.10 **
9 11.06 (4.12) 0.09 ** 0.10 **
Waist Circumference (mm)
26 798.68 (96.40) 0.14 *** 0.24 ***
32 841.81 (110.95) 0.11 *** 0.25 ***
38 858.39 (122.84) 0.12 *** 0.26 ***
Fat Mass (kg)
32 21.41 (10.54) 0.10 ** 0.23 ***
38 23.59 (10.96) 0.11 ** 0.27 ***
Gestational and Childhood Growth
Birthweight (kg) 3.38 (0.52) 0.00 0.07 *
Weight Gain Birth - 3 years (kg) 11.31 (1.52) 0.09 * 0.02
Adiposity Rebound
Age (years) 6.11 (1.10) -0.13 *** -0.21 ***
Body Mass Index (kg/m
2
) 15.57 (1.00) 0.17 *** 0.23 ***
Correlation ( r ) with 
Genetic Risk Score
Correlation ( r ) with 
Family History Score
     
 
Table 3.2. Polygenic Risk for Adult Obesity is Mediated by Developmental Phenotypes of Rapid Early Growth. Panel A presents the 
analysis of mediation of genetic risk for obesity by birth-3 weight gain. Panel B presents the analysis of mediation of genetic risk for 
obesity by age and BMI at adiposity rebound.  The columns labeled  “Bivariate Models” present bivariate effects (relative risks and 95% 
confidence intervals) for the genetic risk score and the developmental phenotypes from Poisson regression models. The columns labeled 
“Multivariate Model” present the independent effects of the genetic risk score and the developmental phenotypes from multivariate 
Poisson regression models. Mediation analyses are reported in the final row of each panel. Mediation Ratios were calculated from the 
indirect and direct effects estimated from structural equations (Appendix B, Supplemental Table 3). The mediation ratio describes how 
much of the effect of genetic risk is mediated by the developmental phenotype. All analyses were adjusted for sex and included the 
n=856 European-descent individuals in the analysis sample. Birth-3 weight gain and adiposity rebound measures were standardized to 
have means of 0 and standard deviations of 1 for analyses.  
 
Panel A. Polygenic Risk for Obesity is Partly Mediated by Weight Gain Between Birth and Age 3 Years
Bivariate                                
Models
Multivariate           
Model
Bivariate                                
Models
Multivariate           
Model
Bivariate                                
Models
Multivariate           
Model
Bivariate                                
Models
Multivariate           
Model
Genetic Risk Score 1.39 1.30 1.37 1.34 1.23 1.21 1.37 1.32
(1.08, 1.81) (1.00, 1.69) (1.13, 1.68) (1.10, 1.63) (1.08, 1.39) (1.07, 1.37) (1.09, 1.74) (1.05, 1.67)
Birth-3 Weight Gain 1.78 1.72 1.32 1.28 1.15 1.13 1.44 1.39
(1.38, 2.30) (1.33, 2.22) (1.10, 1.59) (1.06, 1.54) (1.02, 1.31) (1.00, 1.28) (1.15, 1.80) (1.12, 1.73)
Mediation Ratio                                 0.16 0.07 0.06 0.10
Sobel Test of Mediation p=0.021 p=0.057 p=0.118 p=0.037
Panel B. Polygenic Risk for Obesity is Partly Mediated by Age and Body Mass Index at Adiposity Rebound
Bivariate                                
Models
Multivariate           
Model
Bivariate                                
Models
Multivariate           
Model
Bivariate                                
Models
Multivariate           
Model
Bivariate                                
Models
Multivariate           
Model
Genetic Risk Score 1.39 1.18 1.37 1.20 1.23 1.14 1.37 1.20
(1.08, 1.81) (0.93, 1.49) (1.13, 1.68) (1.00, 1.45) (1.08, 1.39) (1.01, 1.29) (1.09, 1.74) (0.96, 1.50)
Age (years) at Adiposity Rebound 0.57 0.57 0.66 0.66 0.77 0.78 0.66 0.66
(0.48, 0.68) (0.48, 0.68) (0.58, 0.75) (0.58, 0.75) (0.70, 0.85) (0.70, 0.85) (0.57, 0.76) (0.57, 0.76)
2.13 2.09 1.61 1.56 1.35 1.33 1.72 1.68
(1.70, 2.66) (1.66, 2.64) (1.36, 1.89) (1.32, 1.85) (1.20, 1.51) (1.19, 1.49) (1.44, 2.05) (1.39, 2.02)
Mediation Ratio                                 0.58 0.44 0.41 0.45
Sobel Test of Mediation p<0.001 p<0.001 p<0.001 p<0.001
Body Mass Index at Adiposity 
Rebound
Chronic Obesity (ages 15-38 years)
8% (n=72)
Age Range / % Ever Obese (n)
Obesity in the Thirties
22% (n=191)
Obesity in the Teenage Years
5% (n=47)
Obesity in the Twenties 
11% (n=96)
3
5
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Figure 3.1. Developmental phenotypes of rapid early growth hypothesized to mediate 
polygenic risk for obesity. The genetic epidemiology of obesity indicates that a large number of 
common polymorphisms each contribute small, additive increments to risk for obesity.
13, 89
 The 
combined influence of these polymorphisms can be summarized in a polygenic risk profile.
65
  
The developmental epidemiology of obesity highlights three developmental phenotypes of rapid 
early growth that predispose children to become obese in later life: (1) growth during gestation, 
(2) postnatal growth, and (3) adiposity rebound.
134
 
10
 We tested the hypothesis that these 
developmental phenotypes would mediate polygenic risk for adult obesity.    
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Figure 3.2. Individuals with higher obesity genetic risk scores (GRSs) were larger and grew 
more rapidly as children and as adults. The solid line represents the population mean trajectory 
(average genetic risk). Dashed lines are for subgroups +/- 1 standard deviation of the GRS (high 
and low genetic risk). Trajectories were derived from the life-course growth model (intercept 
fitted at age 13 years; linear and quadratic slopes fitted over ages 3-13 years and 13-38 years) 
including intercept and linear slope effects for the genetic risk score. Analyses included n=856 
European-descent individuals.  
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Figure 3.3. Individuals with higher genetic risk scores were more likely to be obese across two 
decades of adult follow-up. Error bars reflect 95% confidence intervals (CIs). The genetic risk 
score was dichotomized at the sample mean to create low and high genetic risk categories. 
Relative risks (RR) and 95% CIs are reported from Poisson regression models adjusted for sex 
including the n=856 European-descent individuals in the analysis sample.  
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Figure 3.4. The genetic risk score contained information about children’s growth and their obesity risk that was not available in their 
family histories. Genetic risk and family history made independent and additive contributions to life-course growth predictions and to 
adult obesity risk in n=856 European-descent individuals. Panel A shows that genetic risk and family history made additive contributions 
to growth predictions. Panel B shows that genetic risk and family history made additive contributions to children’s risk of becoming 
obese. Error bars reflect 95% confidence intervals.  Statistical analyses illustrating the independence of the genetic risk score and family 
history in predicting growth and obesity risk are presented in Supplementary Table 2 (Appendix B). 
                     
        
15
20
25
30
3 8 13 18 23 28 33 38
B
o
d
y
 
M
a
s
s
 
I
n
d
e
x
Age (years)
0%
10%
20%
30%
40%
%
 
O
b
e
s
e
Teens 20s 30s       Chronic 
(15-38)
Low Familial Risk, Low Genetic Risk 
Low Familial Risk, High Genetic Risk 
High Familial Risk, Low Genetic Risk 
High Familial Risk, High Genetic Risk 
3
9
 
  
 
 
CHAPTER 4. 
POLYGENIC RISK ACCELERATES THE DEVELOPMENTAL PROGRESSION TO 
HEAVY, PERSISTENT SMOKING AND NICOTINE DEPENDENCE: 
EVIDENCE FROM A 4-DECADE LONGITUDINAL STUDY 
 
INTRODUCTION 
Cigarette smoking is a costly, prevalent public health problem. The US Centers for Disease 
Control and Prevention attribute 400,000+ deaths and $95 million in lost productivity to smoking during 
2000-2004.156 About 20% of adults still smoke daily despite widespread knowledge of smoking’s health 
effects and increasing economic costs to smokers due to rising taxes.157 Thus, more effective 
interventions to prevent smoking, motivate smoking cessation, and prevent relapse back to smoking are 
needed.158-160 
  Studies of twins suggest that genetic differences between individuals play an important role in 
smoking behavior, cessation, and in response to anti-smoking interventions.161 Recent genome-wide 
association studies (GWAS) in adult smokers and former smokers revealed genes that relate with 
genome-wide significance to smoking quantity (number of cigarettes smoked per day).162-164 These 
genes are already being used in clinical applications; e.g., to predict smoking cessation likelihood and in 
pharmacogenetic analyses.165-169  An important additional step in the translation of these GWAS findings 
is to test if genetic markers that predicted smoking quantity in GWAS also predict the development of 
smoking behavior in adolescence.170, 171 This question is of critical importance for public health practice 
as intervention to disrupt genetic risk is likely to be most effective early in the development of 
dependence. Important developmental phenotypes in the pathogenesis of adult dependence include 
smoking initiation, conversion to daily smoking during adolescence, and rapid progression to heavy 
smoking.172 Early, rapid progression from smoking initiation to heavy use is a signal risk for adult nicotine 
dependence.173-176 Therefore, this research tested relations of GWAS-identified genetic risk with both 
adolescent and adult smoking phenotypes and then determined the extent to which genetic effects on 
the former affected the adult phenotype outcomes. 
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In this study, we tested prospective associations between genetic risks and adolescent 
developmental and mature adult phenotypes of smoking behavior (Figure 4.1). We examined genetic 
risks in the Dunedin Study, a birth cohort (n=1,037) followed to age 38 years with >90% retention. We 
collected smoking behavior data at 8 assessments spanning ages 11-38 years. This allowed us to study 
the effects of genetic risk in the cohort as members initiated smoking during adolescence, converted to 
daily smoking and progressed to heavy smoking during the teenage and young adult years, and as they 
developed nicotine dependence and struggled with cessation in their 20s and 30s. We tested whether 
individuals at higher genetic risk progressed more rapidly from smoking initiation to heavy smoking, if 
they smoked more heavily as adults, if they were more nicotine dependent, and if they were more likely 
to fail in their cessation attempts. Finally, we tested the hypothesis that genetic risk accelerates the 
developmental progression from smoking initiation to heavy smoking, and this, in turn, increases the 
severity of adult smoking problems such as heavy, intractable smoking and nicotine dependence.  This 
model has relevance to public health interventions that might delay the developmental progression to 
heavy smoking.  
METHODS 
Sample 
Participants are members of the Dunedin Multidisciplinary Health and Development Study, a 
longitudinal investigation of health and behavior in a complete birth cohort. Study members (N=1,037; 
91% of eligible births; 52% male) were all individuals born between April 1972 and March 1973 in 
Dunedin, New Zealand, who were eligible for the longitudinal study based on residence in the province 
at age 3 and who participated in the first follow-up assessment at age 3. The cohort represents the full 
range of socioeconomic status in the general population of New Zealand’s South Island and is primarily 
white. Assessments were carried out at birth and at ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, and, most 
recently, 38 years, when 1,007 Study members were still alive, with over 90% retention.  At each 
assessment wave, study members are brought to the Dunedin research unit for a full day of interviews 
and examinations. The Otago Ethics Committee approved each phase of the study and informed consent 
was obtained from all study members. 
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Measures  
Genetic Risk Score 
A challenge for developmental research following-up GWAS discoveries is that effect sizes for 
individual single-nucleotide polymorphisms (SNPs) are small; the largest effects for smoking quantity 
approach a change of 1 cigarette per day per risk allele. Moreover, many of the longitudinal studies with 
data necessary to investigate developmental phenotypes are underpowered to test single-SNP effects.54 
However, there is evidence that smoking-associated loci make additive contributions to risk, 
recommending aggregating risk alleles.59, 60, 177 Summing risk alleles across GWAS-identified SNPs to 
compute a “genetic risk score” (GRS) yields a quantitative index of genetic risk with a normal 
distribution65 and a potentially larger effect size. 
We derived the genetic risk score (GRS) from 3 recent meta-analyses of GWAS that used as their 
phenotype cigarettes smoked per day.162-164  To construct the genetic risk score (GRS), we considered 
single-nucleotide polymorphisms (SNPs) from regions with genome-wide significant associations in at 
least two meta-analyses: All 3 meta-analyses identified SNPs in the q25.1 region of chromosome 15 
containing the CHRNA5-CHRNA3-CHRNB4 gene cluster. Two meta-analyses identified SNPs in the q13.2 
region of chromosome 19 containing the gene CYP2A6. These genes influence nicotine response and 
nicotine metabolism, have been linked with nicotine dependence, and are candidate genes in research 
into the development of smoking behavior.60, 178-185 Therefore, we focused our inquiry on GWAS-
identified SNPs in these two regions. In 15q25.1, we selected the SNPs rs16969968, rs6495308, 
rs8032771, and rs12595538. The SNPs rs16969968 and rs6495308, which fall within the CHRNA5-
CHRNA3-CHRNB4 gene cluster, were shown previously to have independent associations with smoking 
quantity163 (see also186). The SNPs rs8032771 and rs12595538, which are located downstream of the 
CHRNA5-CHRNA3-CHRNB4 gene cluster, were in weak linkage-disequilibrium (LD) with rs16969968 and 
rs6495308 (R2≤0.10), and were genome-wide significant in the largest meta-analysis162 (p<1x10-16 for 
both; p-values for these SNPs were not published in the other two meta-analyses). In 19q13.2, we 
selected the SNPs rs7937 and rs4105144. We summed alleles associated with higher smoking quantity 
to calculate the GRS. 
To validate this GRS, we used independent data from the Atherosclerosis Risk in the 
Communities (ARIC) sample, accessed through the NIH database of Genotypes and Phenotypes 
(dbGaP).81 When a GRS SNP was not available in ARIC, we selected the closest LD proxy for that SNP to 
include in the GRS. Among European-descent ARIC participants, each standard deviation (SD) increase in 
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the GRS predicted a 0.99 pack-year increase in lifetime cigarette consumption among individuals who 
had ever smoked (p=0.001) and a 0.65 cigarette increase in daily consumption among these ever 
smokers (p=0.001).  
Dunedin cohort genotyping was conducted with an Illumina BeadPlex Array using DNA extracted 
from whole blood (93% of the sample) or buccal swabs (7% of the sample). GRS SNPs or proxies (linkage 
R2≥0.85) were called successfully in >95% of European-descent study members (Appendix C, 
Supplemental Table 4.1). These n=880 individuals formed the analysis sample. Cohort members carried 
an average of 7.06 of 12 possible risk alleles (SD=2.27). The GRS was standardized to have mean=0 and 
standard deviation=1 for analyses (genetic risk Z-score).  
Family History of Smoking  
Family histories of smoking were available for 99% of the cohort. The family history consisted of 
reports of smoking history provided by study members and both parents for study members’ siblings, 
parents, and grandparents. The family history was summarized as the proportion of family members in 
the pedigree who were ever regular smokers, adjusted to account for differences in genetic relatedness 
to the proband of first- and second-degree relatives.187  
Smoking Behavior  
The developmental progression of smoking behavior in the Dunedin cohort is described in 
Figure 2 Panel A. Measurement of adolescent developmental phenotypes and mature phenotypes of 
smoking behavior are described in Figure 4.2 Panel B.  
Analyses 
Data analysis was divided into three parts: First, we analyzed associations between the GRS and 
developmental phenotypes of smoking behavior. Second, we analyzed associations between the GRS 
and mature phenotypes. Third, we tested whether developmental phenotypes mediated associations 
between the GRS and mature phenotypes. We analyzed continuous data using ordinary least squares, 
count data using negative binomial, and categorical data using Poisson regression models. We used 
longitudinal data analysis techniques to account for differences in exposure time: We analyzed hazards 
of smoking initiation, progression to heavy smoking, becoming nicotine dependent, and relapsing from a 
quit attempt using Cox proportional hazard models. To account for differences in the frequency with 
which study members attempted cessation, we constructed panel datasets that included one 
observation per study member per assessment (for the age 18-32 data) and one observation per study 
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member per quit attempt (for the life-history calendar data). We used these panel datasets to analyze 
the genetic effect on smokers’ risks of cessation failure during ages 18-32 years and on their hazards of 
relapse during ages 32-38 years. We accounted for non-independence of repeated observations of 
individuals using generalized estimating equation models of risks and conditional risk-set models of 
hazards.188, 189 Analyses were adjusted for sex and conducted using Stata 11.0.145 Panel-data models 
were fitted to longitudinal repeated-measures data using “XT” and “ST” commands in Stata 11.0. We 
evaluated mediation using structural equation modeling.140, 142, 143 Unless otherwise noted, effect-sizes 
are presented for one-unit increases in the genetic-risk Z-score (GRS). 
 
RESULTS 
Genetic risk was not related to smoking initiation. The GRS was not associated with whether 
individuals initiated smoking or with the timing of initiation (relative risk (RR) for smoking 
initiation=0.98, 95% CI [0.95-1.02], cumulative hazard ratio (HR) for initiation=1.01, [0.94-1.09] based on 
a one-unit increase in GRS z-score). Subsequent analyses focused on the 627 Dunedin cohort members 
who initiated smoking at some point during follow-up (Figure 4.2).  
Genetic risk was related to the progression of smoking behavior. Individuals at higher genetic 
risk were more likely to progress to smoking ≥20 cigarettes/day and did so more rapidly (HR=1.35 [1.14-
1.58]). Figure 3 Panel A shows the cumulative hazards for smoking ≥20 cigarettes/day for individuals at 
low, average, and high genetic risk. An unexpected finding was that individuals who initiated smoking 
but who did not progress to daily smoking or to heavy smoking, so-called “chippers”, were at the lowest 
genetic risk of any group in the cohort (Figure 4.3 Panel B).  
Adolescents at higher genetic risk were more likely to convert to daily smoking early and to 
progress rapidly from initiation to smoking ≥20 cigarettes/day. Among ever-smokers, 19% converted to 
daily smoking by age 15 years (early conversion) and 10% progressed to smoking ≥20 cigarettes/day by 
age 18 years (rapid progression to heavy smoking). Each unit increase in the GRS predicted a 24% 
increase in the relative risk of early conversion (RR=1.24 [1.06-1.45]) and a 43% increase in the relative 
risk of rapid progression (RR=1.43 [1.10-1.86]).  
 Individuals at higher genetic risk smoked more heavily across the lifespan. Individuals at higher 
genetic risk accumulated more pack-years across 38 years of follow-up. Each one-unit increase in the 
GRS predicted an additional pack-year in lifetime cigarette consumption among ever-smokers (B=1.05 
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[0.36-1.73]) (Figure 4.4 Panel A). We also analyzed the persistence of heavy smoking as the number of 
assessments at which individuals smoked ≥20 cigarettes per day. Individuals at higher genetic risk 
smoked heavily at more assessments (incidence rate ratio (IRR) for number of assessments as a heavy 
smoker=1.26 [1.07-1.49]).  
Smokers at higher genetic risk were more likely to develop nicotine dependence. Through age 
38 years, 27% of ever-smokers developed nicotine dependence. Individuals at higher genetic risk were 
more likely to become nicotine dependent compared to individuals at lower genetic risk and were 
nicotine dependent at more assessments (HR for nicotine dependence =1.27 [1.09-1.47]; IRR for 
assessments with nicotine dependence=1.22 [1.06-1.41]) (Figure 4.4 Panel B). 
 Smokers at higher genetic risk were more reliant on smoking as a coping strategy. In addition 
to testing genetic associations with nicotine dependence, we also asked whether cohort members at 
higher genetic risk were more reliant on smoking to cope with stress. Among study members who 
smoked daily during ages 32-38 years (n=261), those at higher genetic risk relied more heavily on 
smoking as a coping strategy (B=0.22 [0.10-0.33]).  
Smokers at higher genetic risk were more likely to experience cessation failure. Assessment of 
cessation failure is challenging.190 Therefore, we looked for convergent evidence across two approaches 
to testing genetic associations with cessation failure. We first analyzed study members’ reports of 
cessation failure between ages 18-32 years. Across 14 years of follow-up, n=405 cohort members 
smoked daily. 90% of this group made at least one quit attempt and 51% reported a cessation failure at 
one or more assessments. Cohort members at higher genetic risk were more likely to experience 
cessation failure in their quit attempts (RR=1.11 [1.01-1.22]). 
We next used the month-to-month life history calendars to look closely at cohort members’ 
smoking behavior during their 30s, when cessation was most common. Across 96 months of follow-up, 
n=261 cohort members smoked daily.  52% of these smokers made a quit attempt lasting one month or 
more. Relapse was common (occurring in 61% of quitters). Quitters at higher genetic risk were more 
likely to relapse and did so sooner after quitting (HR=1.22 [1.02-1.45]). Only 19% of daily smokers 
achieved successful cessation (abstinent for ≥1 year through age 38).  Smokers at higher genetic risk 
were less likely to have achieved successful cessation at the end of follow-up (RR=0.73 [0.57-0.93]) 
(Figure 4.4 Panel C).   
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Early conversion to daily smoking and rapid progression to heavy smoking mediated genetic 
associations with adult smoking problems. We derived an index of adult smoking problems from a 
principal components analysis of 3 indicators: a) pack-years smoked by age 38 years; b) total number of 
Fagerstrom symptoms across assessments; and c) the number of assessments at which study members 
reported cessation failure. The adult smoking problems factor explained 78% of the variance in the 3 
indicators (factor loading for heavy smoking=0.61; for nicotine dependence=0.60; for cessation 
failure=0.52). Individuals at higher genetic risk developed more smoking problems in adulthood (r=0.10, 
p=0.012). We next tested whether this association was accounted for by the more rapid developmental 
progression of smoking behavior among individuals at higher genetic risk. 81% of this association was 
accounted for by the two adolescent developmental phenotypes of early conversion to daily smoking 
and rapid progression to smoking≥20 cigarettes/day (Appendix C, Supplemental Table 4.2). Among 
individuals who did not exhibit these adolescent developmental phenotypes of rapid smoking 
progression, genetic risk was uncoupled from the development of smoking problems in adulthood 
(r=0.05, p=0.176).     
The genetic risk score captured information that could not be ascertained from a family 
history of smoking behavior. The family history score and the GRS were uncorrelated (r=0.011).  Both 
family history and the GRS predicted study members’ smoking phenotypes (Table 4.1). When family 
history and the GRS were both standardized and included in regression models simultaneously, GRS 
coefficients were unchanged and remained statistically significant. Thus, the GRS contained different 
information about risk for developmental and mature phenotypes of smoking behavior compared to 
family history.  
COMMENT 
Etiological research on substance abuse highlights the importance of progression from initiation 
to heavy use during adolescence in the development of dependence in adulthood.47, 48  In this study, we 
linked the developmental progression of smoking behavior to genetic risk. We derived a genetic risk 
score (GRS) from GWAS of smoking quantity. This GRS was not related to smoking initiation. However, 
individuals at higher genetic risk did progress more rapidly from smoking initiation to heavy smoking. In 
fact, daily smokers who did not progress to heavy use were at lower genetic risk than individuals who 
never smoked. Critically, high genetic risk led individuals to become persistent heavy smokers, develop 
nicotine dependence, and struggle with cessation failure only to the extent that they progressed rapidly 
from smoking initiation to heavy smoking during adolescence. 
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Previous research has related polymorphisms in the genes included in our genetic risk score to 
developmental phenotypes of smoking behavior60, 177, 181-184 and to mature phenotypes of adult smoking 
problems.178-180, 191, 192 To our knowledge, ours is the first study to track the relations of particular genetic 
risk variants with the development of smoking behavior from initiation through conversion to daily 
smoking and progression to heavy smoking, and on to the mature phenotypes of persistent of heavy 
smoking, nicotine dependence, and struggles with cessation through mid-life. Moreover, this extended 
follow-up allowed us to show, for the first time, that GWAS-identified variation in 15q25.1 and 19q13.2 
influences adult smoking problems through a pathway mediated by adolescent progression from 
smoking initiation to heavy smoking. Our study is also the first to show that GWAS-identified SNPs 
provide information about smoking risks that cannot be ascertained from a family history, including 
information about risk for cessation failure.  
These findings should be considered in light of three limitations. First, the Dunedin Study sample 
consisted of European-descent individuals, as did the samples analyzed in the GWAS used to develop 
the GRS. Replication in other populations is needed.193 Second, our analyses of cessation were subject to 
censored data. The life history calendars ended at the age 38 follow-up and thus the data do not reflect 
relations with phenotypic events occurring after this age.  Also, self-reports of temporally remote events 
could be inaccurate due to forgetting or other biases.  Third, the four-decades of follow-up in the 
Dunedin Study coincided with major secular events such as bans against smoking in the workplace. 
Comparisons of cohorts born at different times might elucidate gene-policy interactions in smoking 
behavior and reflect the generalizability of the current findings.194  
Despite these limitations, this study has implications for etiological research and public health. 
With respect to etiology, our study makes 3 contributions: First, Next Gen sequencing studies and other 
efforts to ascertain causal variants responsible for GWAS signals may maximize their discovery potential 
by focusing on samples of young people strategically selected to reflect important developmental 
transitions. Such work could use experimental designs to test hypotheses about mechanisms of genetic 
risk on post-initiation phenotypes. Second, we demonstrated that a genetic risk score based on the 
assumption of additive risks can be used to follow-up GWAS results in a birth cohort far smaller than the 
original discovery samples. Future etiological research can use genetic risk scores to apply GWAS results 
to longitudinal studies. Third, results are consistent with the hypothesis in pediatric medicine that some 
adolescents, after only experimental use, are prone to quickly become heavy users and dependent.11  
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Turning to public health, our research adds a genetic dimension to long-standing arguments that 
early prevention could be a critical strategy in reducing cigarette consumption.42 Specifically, our 
findings and others’181 suggest that initiatives that disrupt the developmental progression of smoking 
behavior, such as surtaxes and age restrictions on tobacco purchases, may ameliorate some genetic 
risks.195 Moving beyond population-level prevention, we showed that information about smoking risk 
captured in a score composed of GWAS-identified variants was independent of information that could 
be derived from a family history of smoking behavior. This novel finding suggests that genetic 
information could be used to identify “high-risk” youngsters for targeted prevention.11, 196 However, the 
associations we detected between the genetic risk score and smoking phenotypes were small in 
magnitude. Small effect sizes do not preclude public health relevance,197 but they do caution against the 
use of genetic information to evaluate risk in individuals;7  children that our study would classify at high 
genetic risk are not guaranteed to become addicted if they try smoking and, even more importantly, 
children we would classify at low genetic risk are not immune to addiction. The public health use of the 
current findings must be tempered with recognition that most “risk-associated” genetic variation does 
not determine poor health outcomes and, correspondingly, its absence does not guarantee 
protection.103, 198  
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Table 4.1. Effect sizes for genetic and family history associations with developmental and clinical 
phenotypes of smoking behavior.  Effect sizes are for a one standard deviation increase in the predictor 
variable (the genetic risk score or the family history score). Effect size measures are Pearson 
correlations, ‘r’; relative risks ‘RR’ from Poisson regression models; incident rate ratios ‘IRR’ from 
negative binomial regression models; hazard ratios ‘HR’ from Cox proportional hazard models; and beta 
coefficients ‘B’, from linear regression models. All models were adjusted for sex. Effect-size measures 
with a star ‘*’ were estimated from longitudinal datasets including repeated observations of individuals 
over time. Effect sizes in gray text were not statistically significant at the α=0.05 level. 
  
Developmental Phenotypes
Smoking Initiation (among n=880 Individuals; n=627 Who Ever Initiated Smoking)
0.98 1.12
[0.95-1.02] [1.07-1.17]
1.01 1.06
[0.94-1.09] [0.98-1.15]
Progression from Initiation to Heavy Smoking (among n=627 Ever-Smokers)
1.24 1.52
[1.06-1.45] [1.27-1.83]
1.43 1.68
[1.10-1.86] [1.26-2.24]
1.35 1.47
[1.14-1.58] [1.23-1.76]
Mature Phenotypes
Heavy Smoking Persistence (among n=627 Ever Smokers)
1.05 2.49
[0.36-1.73] [1.80-3.19]
1.26 1.49
[1.07-1.49] [1.24-1.80]
Nicotine Dependence (among n=627 Ever Smokers)
1.27 1.53
[1.09-1.47] [1.29-1.80]
1.22 1.50
[1.06-1.41] [1.28-1.75]
Smoking to Cope with Stress (Ages 32-38 Years, Among n=261 Daily Smokers)
0.22 0.09
[0.11-0.32] [-0.05-0.23]
Cessation Failure
Ages 18-32 years (n=405 Daily Smokers; among n=364 who Attempted Cessation)
1.11 1.11
[1.01-1.22] [1.00-1.23]
Ages 32-38 Years (n=261 Daily Smokers; n=136 Who Quit for ≥1 Month)
1.22 0.96
[1.02-1.45] [0.79-1.17]
0.73 0.94
[0.57-0.93] [0.73-1.20]
 
Likelihood of Successful Cessation (among 
daily smokers)
Risk of Cessation Failure
BSmoking to Cope Score
RR
HR*
RR*
Family History ScoreGenetic Risk Score
p=0.758
Correlation between the Genetic Risk Score and 
the Family History Score
0.011
Effect Size 
Measure
r
Count of Assessments with Nicotine 
Dependence
IRR
HR*
HR*
RR
HR*
RR
RR
IRR
Ever-Smoker Status
Lifetime Cigarette Consumption (Pack Years)
Hazard of Relapse Following Quit Attempts 
Lasting ≥1 Month
B
Early Conversion to Daily Smoking (by Age 
15 Years)
Lifetime Hazard to Becoming Nicotine 
Dependent (≥4 Fagerstrom Symptoms)
Count of Assessments Smoking ≥20 
Cigarettes/Day
Lifetime Hazard for Smoking ≥20 
Cigarettes/Day
Rapid Progression to  Smoking ≥20 
Cigarettes/Day  (by Age 18 Years)
Lifetime Hazard for Smoking Initiation
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Figure 4.1. Genetic risk and the developmental progression of smoking behavior. In the hypothesized 
model, genetic risk influences the mature phenotypes of heavy smoking persistence, nicotine 
dependence, and cessation failure through a pathway mediated by three developmental phenotypes: 
smoking initiation, conversion to daily smoking; and progression to heavy smoking.  
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Figure 4.2. Smoking behavior in the Dunedin cohort. 
 
Panel A. Developmental Progression of Smoking Behavior in the Dunedin cohort. Study 
members reported their smoking status during in-person assessments at ages 11 (percent ever-
smokers=7%), 13 (13%), 15 (62%), 18 (66%), 21 (70%), 26 (70%), 32 (71%), and 38 years (71%) 
and their daily cigarette consumption at ages 13 (percent daily smokers=1%), 15 (14%), 18 
(31%), 21 (34%), 26 (35%), 32 (30%), and 38 years (20%). We assessed nicotine dependence 
using the Fagerstrom Test of Nicotine Dependence (FTND),
199
 completed by study members at 
the age-21, -26, and -38 assessments. We assessed cessation failure using study members’ 
reports of quit attempts and outcomes at the ages 18, 21, 26, 32, and 38 assessments. 
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Panel B. Measurements of Developmental and Mature Smoking Phenotypes 
Developmental Phenotypes N % 
Initiation. Age at which study members reported first smoking at least 
occasionally.  Survival time to initiation was calculated as the age at which a 
study member first began smoking at least occasionally. The 627 cohort 
members who initiated smoking represent 71% of the n=880 European-
descent cohort members with available genetic data.  
627   
Conversion Daily Smoking. The first assessment at which a study member 
smoked ≥1 cigarette per day. 
418 67% 
Early Conversion to Daily Smoking. Daily smoker at the age 15 assessment. 
Most study members who ever converted to daily smoking did so by the age-
18 assessment (74%). Therefore, we defined “early conversion” to daily 
smoking as having converted by the previous assessment at age 15 years.  
121 19% 
Progression to Smoking ≥20 Cigarettes/Day. Ever a smoker of ≥20 cigarettes 
per day, ages 13-38 years. "Survival time" to heavy smoking was calculated as 
the number of years between initiation and the first assessment at which a 
study member smoked ≥20 cigarettes per day. 
155 25% 
Rapid Progression to Heavy Smoking. Smoker of ≥20 cigarettes per day by age 
18 years. Most study members who ever became heavy smokers progressed to 
smoking ≥20 cigarettes/day by the age-21 assessment (63%). Therefore, we 
defined “rapid progression” as progression to smoking ≥20 cigarettes/day by 
the previous assessment at age 18 years.  
61 10% 
Mature Phenotypes M SD / N % 
Lifetime Cigarette Consumption (Pack Years). Pack-years = the number of 
cigarettes smoked per day, divided by 20 and multiplied by the number of 
years smoked at that rate.38 The mean and standard deviation of pack-years 
was calculated for ever-smokers. 
8.39 8.95 
Nicotine Dependence.  Study members completed the Fagerstrom Test of 
Nicotine Dependence (FTND)199 at the age-21, -26, and -38 assessments. The 
FTND was developed to measure the construct of physical dependence and 
includes the facets of needing to smoke in the morning to alleviate overnight 
withdrawal, needing to smoke many cigarettes per day, and invariance in 
smoking behavior, e.g. in the face of illness.200 The FTND produces a 
“Fagerstrom score” score ranging from 0-10. Nicotine dependence is defined 
as a Fagerstrom score ≥4.201, 202 We calculated survival time as years between 
smoking initiation and the first assessment at which a study member was 
nicotine dependent. Percent reflects ever-smokers who became nicotine 
dependent. 
169 27% 
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Smoking to Cope with Stress. Study members were interviewed about how 
they coped with stress associated with their relationships, work, and finances 
at ages 32 and 38 years. Study members rated the extent to which they used 
different coping strategies. One of these strategies was smoking more. Ratings 
of smoking as a coping strategy were averaged and the average was 
standardized to produce a score with mean=0 and standard deviation=1.  
0 1 
Cessation Ages 18-32 years. To assess cessation failure prior to the period 
covered by the life history calendar, we used study member’s reports collected 
at ages 18, 21, 26, and 32 years of whether they had made a quit attempt in 
the past year and whether they had failed in their quit attempt within one 
month. N reflects study members who attempted cessation at least once. 
Percent is calculated from study members who were ever daily smokers 
between ages 18 and 32 years (n=405). 
364 90% 
Cessation Ages 32-38 years. At the age-38 assessment, study members 
completed life history calendars203 detailing their smoking behavior during 
each month from age 32 to age 38 years. Embedding recall of smoking 
behavior in a life-history calendar improves accuracy.204 We used these data to 
identify 2 phenotypes: Relapses were ≥1 months of abstinence followed by ≥1 
months of daily smoking; Successful Smoking Cessation was abstinence for ≥1 
year through the time of the age-38 interview. N reflects study members who 
quit for ≥1 month between ages 32 and 38 years. Percent is calculated from 
study members who became daily smokers by age 32 and were daily smokers 
for ≥1 month during ages 32-38 years (n=261). 
136 52% 
  
 
    
Figure 4.3. A genetic risk score derived from GWAS of smoking quantity is associated with the developmental progression of smoking 
behavior in a birth cohort of European-descent individuals. Panel A shows that individuals at higher genetic risk progressed more rapidly from 
smoking initiation to heavy smoking. Panel A graphs hazard functions for onset of heavy smoking among individuals at low genetic risk (genetic 
risk Z-score=-1, green line), average genetic risk (genetic risk Z-score=0, black line), and high genetic risk (genetic risk Z-score=1, red line). The 
dashed gray line marks the cumulative hazard for individuals at average genetic risk. The hazard function was estimated from a Cox proportional 
hazard model with time since onset of ever-smoking as the exposure time and the first assessment a study member reported smoking ≥20 
cigarettes/day as the failure event. The hazard model included all individuals who ever initiated smoking (N=627). Individuals at higher genetic 
risk progressed more rapidly from smoking initiation to smoking ≥20 cigarettes/day (Hazard Ratio=1.35 [1.15-1.59]). Panel B shows that genetic 
risk was highest among individuals who progressed to heavy smoking and lowest among individuals who initiated smoking but who did not 
progress to heavy smoking. The figure shows the genetic risk Z-sores (+/- 1 standard error) for each group.  “CPD” is “cigarettes per day.” A 
genetic risk Z-score of 0 corresponds to the average genetic risk in the cohort. Error bars reflect standard errors of the sub-group means. 
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Figure 4.4. Genetic risk predicts mature phenotypes of smoking behavior. Panel A shows that 
among individuals who initiated smoking, those at higher genetic risk smoked more cigarettes 
by age 38 years. Ever-smokers were all individuals who initiated smoking by age 38 years 
(N=627). The bars of the histogram graph the percentages of the sample carrying 1-12 risk 
alleles. The dots and standard-error bars reflect average lifetime cigarette consumption (in pack-
years) for ever-smokers carrying 1-3, 4, 5, 6, 7, 8, 9, 10, and 11-12 risk alleles. The regression line 
shows the association between the genetic risk score and pack-years smoked by age 38 years 
(Pearson Correlation r=0.12, p=0.003). Panel B shows that ever-smokers at higher genetic risk 
were more likely to be nicotine dependent. The bars of the chart graph the proportion of ever-
smokers (n=627) at low, average, and high genetic risk (left side) who became nicotine 
dependent (≥4 Fagerstrom symptoms) by age 38 years; and (right side) who were nicotine 
dependent at two or more assessments.  Panel C shows that smokers at higher genetic risk were 
more likely to experience cessation failure during their 30s. The bars of the chart graph the 
proportions of daily smokers at low, average, and high genetic risk (left side) who experienced 
relapse following a quit attempt lasting ≥1 month; and (right side) who achieved successful 
cessation (abstinence ≥1 year) through age 38 years. Percent with relapse was calculated from 
cohort members who quit smoking for ≥1 month during ages 32-38 years (n=136). Percent with 
successful cessation was calculated for cohort members who smoked daily during their 30s 
(n=261). In panels B and C, low genetic risk individuals had GRSs more than 1 standard deviation 
below the cohort mean; average genetic risk individuals had GRSs within 1 standard deviation of 
the cohort mean; and high genetic risk individuals had GRSs more than 1 standard deviation 
above the cohort mean. Error bars reflect standard errors.  
Panel A. 
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Panel B.  
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CHAPTER 5. 
SUMMARY & CONCLUSIONS 
 
 
The research described in the three preceding empirical chapters characterizes the public 
health implications of GWAS-discovered genetic risks for two prevalent and costly sources of 
morbidity and early mortality, obesity and smoking. I used theory-free genetic discovery 
research (genome-wide association studies, “GWAS”) to derive multi-locus profiles of genetic 
risk. I next validated these “genetic risk scores” (GRSs) using data from a large, population-based 
cohort of older adults, the Atherosclerosis Risk in the Communities Study (n=15,792). I then 
used these GRSs to investigate how genetic risk influenced the development of obesity and 
smoking problems in a representative birth cohort (n=1,037) followed through their fourth 
decade of life. Results revealed that (1) GRSs can be used to investigate GWAS-discovered 
genetic risks for obesity and smoking in population-based cohorts much smaller than the 
original GWAS discovery samples; (2) genetic risks identified in GWAS manifest early in the 
development of obesity and smoking through processes that may be amenable to public health 
intervention; (3) the magnitudes of risk that can be predicted using genetic information are 
small; but (4) the risk information provided by genetic markers is independent of information 
available in a family history. These findings have three primary implications: First, they 
recommend of caution in the application of genetic information to predict health risks in 
individuals,
7-9
 but suggest promise as more powerful but less common genetic risks are 
discovered in the continuing evolution of genomic research. Second, findings suggest that 
developing samples of children and adolescents should be a focus in genetic discovery research. 
Third, findings and add a genetic dimension to arguments for early intervention and may inform 
the best strategies likely to prevent obesity and smoking.
10, 11
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I. Implications for Research and Public Health 
A. Genetic risk scores composed of genome-wide association study discoveries can provide 
valid measures of inherited risk for obesity and smoking. GRSs for obesity and smoking derived 
by summing risk-associated alleles across panels of GWAS-discovered SNPs are associated with 
quantitative traits (e.g. body mass index, smoking quantity) and clinical endpoints (e.g. obesity, 
nicotine dependence). These associations can be reliably detected in samples far smaller than 
those used for discovery research. In Chapter 3, for example, associations between the smoking 
GRS and cessation outcomes were detected in samples of only a few hundred smokers making 
quit attempts. Thus, GRSs provide a means to follow-up GWAS results in samples that are far 
smaller than those used for discovery research. 
 The validity of a genetic risk score may be specific to the population investigated in the 
GWAS used to construct the score. GWAS rely on “linkage”, the correlation of spatially 
proximate nucleotides in the genome, to leverage measurements of one or two million SNPs to 
infer variation in the entire 15 million plus SNPs in the human genome.
205
 The theory behind 
GWAS is that linkage between measured SNPs and unmeasured SNPs is strong enough that the 
“signal” from an un-measured SNP that is a causal factor in disease etiology can be detected 
through a “proxy” SNP that is measured.
206
 Thus, GWAS-identified SNPs may be proxies in 
linkage with causal variants.
70
 Patterns of linkage vary across population bottlenecks in human 
evolution, e.g. the migration out of Africa.
207
 Therefore, GWAS results may not be consistent 
across ethnic groups defined by these population bottlenecks.
208
 In Chapter 1, the obesity GRS 
was a robust predictor of body mass index and obesity in European-descent cohort members, 
but not in African-descent cohort members. Public health research using GRSs must be careful 
to match the population used for discovery with the population of interest or must validate the 
GRS in a new population before undertaking further etiological research.  
B. The magnitudes of risks measured by GWAS-derived genetic risk scores for obesity and 
smoking are small at the level of the individual, but have implications for public health. Many 
ARIC and Dunedin cohort members at low genetic risk became obese or developed smoking 
problems. Similarly, many members of these cohorts at high genetic risk remained thin or never 
developed smoking problems. In the population based cohorts examined in Chapters 1-3, the 
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GRSs explained roughly 1% of population variance in the relevant outcomes. Consistent with 
prior research,
209
 analyses in Chapter 1 show that a GRS explaining such a small fraction of 
variance in a health trait or behavior is not useful for individual prediction. Yet, the risks 
predicted by the GRSs were far from trivial. In analyses presented in Chapter 2 each 1-unit 
increase in the obesity GRS predicted a 40% increase in risk for chronic adult obesity. In analyses 
presented in Chapter 3, each 1-unit increase in the smoking GRS predicted a 30% increase in the 
hazards for becoming a heavy smoker and for developing nicotine dependence. Thus, these 
GRSs predict risks that are comparable to or in excess of risks that can be predicted by many 
other biomarkers considered of interest in the context of public health research.
210
 
Interventions that effectively ameliorated substantive portions of the genetic risks measured by 
these GRSs could reduce population rates of obesity and smoking and generate substantial 
improvements in health and substantial reductions in healthcare spending.
197
   
C. Information captured in genetic risk scores for obesity and smoking is different from 
information that can be obtained from a family history.  To have public health utility, measured 
genetic variation must provide new information over and above that already available in family 
history.
67
 Therefore, this dissertation research tested the independence of risk scores derived 
from GWAS discoveries and from family histories. Chapters 2 and 3 report tests of the 
independence of the GRSs from risk scores derived from the body mass indexes of children’s 
parents (for obesity) and the smoking behavior of their parents, siblings, and grandparents (for 
smoking). Correlations between GRSs and family-history scores were near zero and were not 
statistically significant. Regression analyses showed that the smoking and obesity GRSs provided 
information about risk that was independent of and additive to information that could be 
obtained from a family history. Thus, in the case of the smoking and obesity phenotypes, the 
genetic variants discovered in GWAS provide new information about risk over and above family 
history.  
Risk effects estimated for family history were consistently larger than risk effects estimated 
for the GRSs, but the differences were small. Therefore, as new genetic discoveries are made, it 
may be useful to revisit the application of genetic information in the context of prospective risk 
assessment, particularly as a means to augment family history-based risk assessments.  
A further note on the unexpected finding that genetic risks discovered in GWAS are un-
related to family histories of obesity and smoking. The GRSs used in this dissertation research, 
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like family-history scores, explain only small fractions of the estimated genetic variance in the 
traits studied (1-4%). Family studies suggest that 50% or more of population variation in body 
mass index and smoking may be attributed to genetic factors.
13, 14
 Therefore, the lack of overlap 
in the few percent of variance explained by each of the genetic risk and family history scores is 
not impossible. Nevertheless, it is somewhat unexpected that GWAS-discoveries should be 
completely unrelated to family histories.  
There are three reasons that GWAS-derived GRSs and family-history scores might show so 
little overlap and these reasons relate to ongoing debate about the genetic architecture of 
common health problems. The debate concerns the importance of common genetic variation 
(like the SNPs measured in GWAS) as compared to rare mutations (variants that occur in <1% of 
the population) in causing common health problems.
35
 GRSs derived from GWAS capture risk 
arising only from common variation. (There is some debate about the role of rare variants 
generating synthetic associations in GWAS, but the balance of evidence suggests that most 
GWAS hits are not artifacts of rare variants.
211-213
) In contrast, family histories comprise all 
genetic variation, both rare and common, in addition to environmental factors shared by family 
members. Therefore, one reason that the GRSs and family history scores might not overlap is 
that the GRSs reflect common genetic variants and family-history scores reflect primarily rare 
genetic variants and environmental risks shared by family members. A second reason that the 
GRSs and family-history scores might not overlap is that family history scores reflect so-called 
“epistatic” interactions among large numbers of common and/or rare variants and interactions 
between genetic variation and environments shared by family members.
214
 A third reason that 
the GRSs and family-history scores might not overlap is that family history scores do reflect 
common variation, but common variation with effects too small to be detected in GWAS. The 
“infinitesimal model”
35
 of trait heritability posits that very large numbers of common genetic 
variants, each with very small effects, contribute to common diseases.
215
 Under this infinitesimal 
model, many causal common variants will escape detection in GWAS unless discovery samples 
grow into the millions and beyond. To the extent that family history scores reflect the combined 
influence of many thousands of common variants with infinitesimal effect sizes, they may not 
overlap with GRSs composed of a handful of common variants with larger effect sizes. Which of 
these explanations is correct has implications for public health.  Family history is established as a 
clinically valid measure of genetic risk.
216-218
 If common SNPs contain entirely different 
information from family history, they may be particularly valuable in the context of risk 
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assessment. However, methods that are better able to address the influence of large numbers 
of SNPs with “infinitesimal” effects, e.g. whole-genome scores,
68
 are needed to resolve this 
question.  
One way researchers have tried to address the problem of measuring genetic risks arising 
from individual variants with “infinitesimal” effects is to derive whole genetic risk prediction 
scores.
68, 219-221
 Whole genetic risk prediction scores (whole genome scores) are derived by using 
large “training” datasets conduct GWAS and assign each SNP in a panel of 500,000-1 million a 
weight reflecting its individual contribution to a given health condition. The whole genome score 
is then calculated by generating a prediction based on the full panel of SNPs or an especially 
promising subset, e.g. the top 1,000 SNPs.
222, 223
 These scores explain more of the variance 
common traits than GRSs composed of genome-wide significant SNPs.
58
  E.g., for body mass 
index, a whole genome score based on 500,000 SNPs may explain as much as 15% of the 
population variance. As compared to the obesity GRS used in this dissertation, the whole 
genome score leverages a 15,000 fold increase in the number of genetic markers used to 
achieve between a 4- and 15-fold increase in predictive power. Thus, until genotyping costs 
decline further, this approach is unlikely to be cost-effective. Moreover, whole genome scores 
perform well in the samples from which they are derived, but much less well in independent 
replication samples.
223, 224
 Therefore, their translational potential remains uncertain. 
Nevertheless, the whole genome approach is a promising direction for genetic risk prediction 
research. Investigating overlap in the risks predicted by whole genome scores and by family 
histories may provide preliminary guidance as to the value of whole-genome scores for clinical 
risk assessment.   
D. Genetic risks for obesity and smoking discovered in genome-wide association studies 
manifest early in development. A critical question for understanding how genetic risk 
contributes to the etiology of obesity and smoking is to identify when in development genetic 
risk manifests.
171
 This question is also central to translational science as intervention to 
ameliorate genetic risk may be most effective if deployed before health problems develop.
31
 
Research presented in chapters 2 and 3 shows that genetic risks identified in GWAS of adult 
samples first manifest earlier in life. Developmental phenotypes of obesity and smoking function 
as critical mediators of genetic risk. In the case of obesity, genetic risk manifests following birth 
and acts to influence childhood growth rates. The adiposity rebound, which is defined as the 
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nadir of the childhood body mass index growth curve, mediates roughly half the genetic effect 
on adult obesity. Children at higher genetic risk reached this nadir of adiposity earlier in life and 
at higher body mass index, and were subsequently more likely to become obese. Independent 
of their age and body mass index at adiposity rebound, children at high genetic risk were no 
more likely to become obese than their low genetic risk peers. In the case of smoking, genetic 
risk manifests following smoking initiation and acts to accelerate the developmental progression 
from experimentation to regular and heavy use during adolescence. Rapid developmental 
progression, defined as conversion to daily smoking by age 15 years or progression to 
smoking≥20 cigarettes/day by age 18 years, mediates the majority of the genetic effect on 
heavy smoking, nicotine dependence, and cessation failure. Individuals at higher genetic risk 
were more likely to progress rapidly in their smoking behavior and, in turn to become persistent 
heavy smokers, nicotine dependent, and unable to quit. Individuals at high genetic risk who did 
not progress rapidly from initiation to regular and heavy use during adolescence were no more 
likely to develop smoking problems in adulthood than their low genetic risk peers.  
Results in Chapters 2 and 3 point to childhood and adolescence as critical stages in the 
manifestation of genetic risk and suggest new phenotypic targets for genetic research as well as 
highlighting possible windows that might be effectively targeted by public health interventions. 
Samples of children and adolescents, particularly those that include repeated measures of 
health outcomes and behaviors collected over time, will be critical to advancing understanding 
of the genetics of smoking and obesity.  
Mediation analyses reported in Chapters 2 and 3 also highlight the importance of early 
intervention. Results presented in Chapter 2 suggest that genetic risks for obesity depend in part 
on rapid childhood growth. In parallel, results presented in Chapter 3 suggest that genetic risks 
for smoking problems depend on a rapid developmental progression from initiation to heavy 
use during adolescence. For individuals who did not exhibit these developmental phenotypes, 
genetic risks were uncoupled from adult health problems. Therefore, public health initiatives 
that encourage more healthy trajectories of growth in early childhood and that prevent or 
reduce smoking among adolescents may help to ameliorate some genetic risks.  
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II. Directions for Future Research 
The research described in the three empirical chapters of this dissertation provides a 
foundation for a program of research to further the translation of genetic discoveries related to 
obesity and smoking risks to improve public health. This program of research includes three 
independent but related research objectives. The first objective is to understand the role of 
genetic risks in the etiology of socioeconomic disparities in health. Social gradients in health 
area major challenge for the healthcare system.
225, 226
 Obesity and smoking are key mediators of 
these health disparities.
227
 Therefore, to the extent that genetic discoveries can inform 
interventions to ameliorate social gradients in obesity and smoking, this would be an area of 
high translational impact. The second objective is to understand mechanisms in brain and in 
behavior that link genetic risk with health outcomes. Identifying mechanisms is a critical step in 
developing effective treatments, and therefore critical to the translation of genetic 
discoveries.
50, 77
 The third objective is to extend the developmental research begun in this 
dissertation into the second half of the life course. Obesity and smoking are major contributors 
to morbidity and premature mortality in older adults.
228
 This dissertation research establishes 
that GWAS discovered genetic risks influence how obesity and smoking develop in early life. The 
next step is to understand how genetic risks relate to changes in body mass index and smoking 
behavior in the second half of the life course.  
Objective 1. To understand the role of genetic risks in the etiology of socioeconomic 
disparities in obesity and smoking. In developed countries, better educated and wealthier 
populations are less likely to become obese or to develop nicotine dependence relative to 
poorer and more poorly educated populations.
229, 230
 This social gradient arises partly from a 
higher burden of environmental risks in lower socioeconomic strata, e.g. less access to health 
behavior promoting resources, targeted advertising of unhealthy foods and cigarettes. But a 
higher burden of discrete environmental risks does not fully account for observed social 
gradients in health.
231
 Therefore, genetics constitute an important and as of yet unstudied 
potential source of these gradients. There are three possible roles that genetics could play in 
contributing to social gradients in health.
232
 First, it is possible that genetic risks are more 
prevalent in lower socioeconomic strata. This is termed “gene-environment correlation” (rGE). 
Second, genetic risks may interact with environmental risks in a synergistic fashion. This is 
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termed “gene-environment interaction” (GxE). Third, genetic risks could be unrelated to social 
gradients in health.     
Preliminary analyses of the Dunedin and ARIC cohorts confirm prior reports of strong social 
gradients in obesity and smoking.
100, 230
 These analyses also reveal that genetic risks for obesity 
and smoking are similarly distributed across socioeconomic strata, i.e. there is no rGE between 
genetic risk and social class. Therefore, to the extent that genetic risks identified in GWAS 
contribute to socioeconomic disparities in obesity and smoking, they must do so in interaction 
with environmental exposures that do show a social gradient.  
Recently, transdisciplinary research at the intersection of medicine, neuroscience, 
endocrinology, and immunology has begun to elucidate a model that describes how 
environmental stressors become biologically “embedded” in ways that contribute to the 
pathogenesis of chronic behavioral and physical health problems.
233
 Such biological embedding 
of stress is likely to be critical to the etiology of health disparities: Disadvantaged populations 
face a higher burden of both severe acute stressors, e.g. violent victimization, and chronic 
stressors, e.g. food insecurity.
234
 Thus, cumulative stress exposures may contribute indirectly to 
socioeconomic disparities in obesity and nicotine dependence through dysregulation of 
processes in body and brain that in turn influence patterns of activity, diet, and smoking 
behavior.
235
  The gene-environment interaction hypothesis augments this biological embedding 
model by positing that certain individuals are more susceptible to the dysregulating effects of 
stress due to differences in their genes.
236
 
One aim of my postdoctoral research will be to identify environmental stress exposures that 
may interact with polygenic risk in the etiology of health disparities. Criteria for candidate 
environmental moderators of genetic risk will (1) exhibit a social gradient; and (2) exert effects 
that coincide with the developmental stages identified in this dissertation as critical in linking 
genetic risks with adult obesity and smoking problems. In addition to these two scientific 
criteria, we will impose a third criterion: that the environmental exposure be amenable to public 
health intervention. The goal of this research is to devise means by which to disrupt the etiology 
of health disparities. Therefore, focusing on environments that can be modified through 
intervention is important to maximizing the translational potential of the research.   
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A second aim will be to test whether the stress exposures identified in the earlier aim alter 
the ways in which genetic risk manifests, either in terms of timing or in terms of magnitude. 
These analyses will utilize data from the Dunedin Study as well as from a new data source: the 
Environmental Risk in Development (E-Risk) Longitudinal Study, a birth cohort of 1,000 pairs of 
same-sex twins and their mothers followed prospectively through the twins’ 18th year.  
Objective 2. Elucidate mechanisms in brain and behavior that link polygenic risks with health 
problems. A key strength of the GWAS approach is that it can leapfrog current biological 
knowledge to make new discoveries. However, this necessitates follow-up research to uncover 
the mechanism through which genetic risk becomes manifest. In my postdoctoral research, I will 
pursue two collaborations to investigate candidate mechanisms through which genetic risk 
influences obesity and smoking.   
(i) Taking polygenic risk inside the brain through imaging genetics research. One 
collaboration will be with brain researchers integrating genetics and neuroscience. Imaging 
genetics research seeks to understand the specific neural processes that connect genetic 
variation with differences in behavior.
237
  Recent research in neuroscience links individual 
differences in neural phenotypes related to reward response, stress response, and attention and 
memory with obesity and with nicotine dependence and smoking cessation difficulties.
238-242
 The 
collaboration with imaging genetics researchers will (1) identify specific neural phenotypes 
implicated in the pathogenesis of obesity and nicotine dependence; and (2) test associations 
between these phenotypes and the genetic risk scores. The goal of this collaboration will be to 
enhance understanding of the neurobiology linking genetic risk with health problems, with the 
aim of identifying specific treatment targets. 
(ii) Taking polygenic risk into the field through genetically informed analysis of 
intervention trials. A second collaboration will be with investigators running intervention trials 
to address risk factors for smoking and obesity. Observational studies implicate behavioral and 
environmental pathways in the manifestation of genetic risk, e.g. sedentary lifestyle seem to be 
important in linking genetic risk with adult obesity and exposure to smoking cues seems to be 
important in linking genetic risks with smoking behavior.
185, 243
 By utilizing intervention designs 
that explicitly manipulate behaviors and environmental triggers, we can better isolate the causal 
role of behaviors and environments in linking genetic risks with health problems. Depending on 
the size of the trials, it may also be possible to test whether individuals at higher genetic risk are 
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more or less susceptible to intervention effects. Collaboration with intervention researchers will 
(1) investigate whether the effects of genetic risk on obesity and smoking are altered by 
experimental manipulations of risk behaviors and environmental cues; and (2) depending on the 
size of the intervention cohorts, investigate whether genetic risks moderate treatment 
response. 
Objective 3. Expand the developmental investigation of polygenic risk for obesity and smoking 
into the second half of the life course. My doctoral research characterized the relationship 
between genetic risks identified in GWAS and the development of obesity and nicotine 
dependence from childhood through mid-life. A next step in this research is to test how genetic 
risk relates to developmental phenotypes of obesity and nicotine dependence in the second half 
of the life course. My preliminary analyses using the ARIC cohort indicate that individuals at 
higher genetic risk lose weight more slowly and reduce their cigarette consumption more 
gradually in older age. Further, my preliminary analyses show that genetic risk for obesity 
predicts increased mortality risk.  
Future research will first attempt to replicate the longitudinal associations between genetic 
risk and slower decline in body mass index and cigarette consumption in the second half of the 
life course. I will then move to address three new questions: (1) how do genetic risks for obesity 
and nicotine dependence relate to more general patterns of morbidity and to mortality risk in 
later life? (2) do health behavior changes following health shocks vary  according to genetic risk? 
and (3) do genetic predispositions to obesity and nicotine dependence relate to health 
outcomes in different ways for individuals with different socioeconomic attainments. 
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APPENDIX A 
Supplementary Materials to Chapter 2 
This supplement describes the application of the 3-stage approach to create a genetic risk score 
(GRS) for obesity. The supplement is organized into 3 sections: The first section describes the 
creation of the obesity GRS: Stage 1. Extraction; Stage 2. Clustering; and Stage 3. Selection.  The 
second section describes analyses comparing the resulting GRS to GRSs created with the best-
guess and top-hits approaches. The final section describes sensitivity analyses to test 
heterogeneity in GRS associations.  
PART 1. CREATING THE OBESITY GRS 
Stage 1. Extraction 
For our 3-stage approach analyses, we considered GWAS of European-descent samples that 
targeted 4 phenotypes: obesity, weight, waist circumference, and body mass index (BMI) 
(hereafter “obesity-related phenotypes”). A search of the NGHRI GWAS Catalog using the HuGE 
Navigator (http://www.hugenavigator.org) identified 16 GWAS that met these inclusion criteria, 
9 of which were published by December 31, 2008 (Supplementary Table 2.1).  
In Stage 1 (Extraction), we compiled association results reported in the manuscripts and 
supplementary materials of the GWAS and extracted rs-numbers and p-values for SNPs 
associated with any of the 4 phenotypes in the discovery or combined discovery and replication 
samples at an alpha level of 1x10
-5
 (n=103 SNPs in the subset of 9 GWAS, n=519 SNPs in the full 
set of 16 GWAS, Supplementary Table 2.2). The significance level of p<1x10
-5
 was the most 
generous threshold at which most GWAS published results and is the threshold used in the 
NHGRI GWAS Catalog 
3
. Associations were not extracted from replication samples because few 
GWAS reported novel associations identified in replication samples and some GWAS did not 
include replication samples or included replication samples of different ethnicity. Discovery 
sample risk SNPs that failed to replicate within an individual GWAS were included because 
replication was evaluated at the level of the GWAS publication rather than the specific test 
sample.  
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Stage 2. Clustering 
In Stage 2 (Clustering), we grouped the extracted SNPs into “LD blocks.” We defined LD blocks 
using data from the HapMap CEU sample (Phase 3), queried using Seattle SNPs’ web-based 
Genome Variation Server (http://gvs.gs.washington.edu/GVS). For each SNP extracted in Stage 1 
(“seeds”), we defined an LD block as the region containing all SNPs in LD with that seed at a 
threshold of R
2
≥0.95. Then, beginning with the block closest to the start of each chromosome, 
we pruned blocks that did not contain a unique seed. This process yielded n=66 LD blocks from 
the subset of 9 GWAS published by December 31, 2008 and n=158 LD blocks from the full set of 
16 GWAS.  
Stage 3. Selection 
In Stage 3 (Selection), we retained LD blocks that we classified as genome-wide significant or as 
replicated. Genome-wide significant LD blocks were those that contained ≥1 SNP associated 
with an obesity-related phenotype at p<1x10
-8
. Replicated blocks were those that contained 
SNPs extracted from ≥2 GWAS. This process yielded n=37 LD blocks clustered around 11 loci on 
chromosomes 1-4,9,11,12,16,18, and 19 from the subset of 9 GWAS and n=69 LD blocks 
clustered around 32 loci on chromosomes 1-6,9,11-14,16,18, and 19 from the full set of 16 
GWAS (Supplementary Tables 2.3, 2.4). Sensitivity analyses relaxing the LD threshold used to 
define LD blocks yielded fewer LD blocks (e.g., for the full set of 16 GWAS, n=58 at an R
2
 
threshold of 0.70), but did not alter the loci identified as genome-wide significant or replicated 
in the original analyses. 
 
PART 2. COMPARING THE 3-STAGE APPROACH GRSs TO THE TOP-HITS AND BEST-GUESS GRSs  
To construct and test our GRSs, we followed-up the LD blocks identified in our 3-stage 
approach analyses in the GWAS dataset from the Atherosclerosis Risk in Communities (ARIC) 
Study. This dataset is publicly available through the National Institutes of Health Database of 
Genotypes and Phenotypes (dbGaP) (http://www.ncbi.nlm.nih.gov/gap, phs000090.v1.p1) and 
is described in the Data section of the main text.  
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We selected SNPs in the ARIC database to include in our two GRSs as follows: We 
defined tag SNPs for each of the LD blocks as SNPs that were in LD with every seed contained in 
the block at R
2
≥0.95. We then matched 1 tag SNP per LD block with a SNP in the ARIC study 
genotype database that met the GENEVA ARIC Project Team’s  quality control criteria 
81
. If no 
tag SNPs in an LD block could be matched in the ARIC database, we relaxed the LD threshold 
used to define a tag SNP until either a) the resulting set of tag SNPs overlapped with tag SNPs 
that we had already matched in the ARIC database, or b) a match with a new SNP in the ARIC 
database was achieved. These analyses yielded a set of n=28 SNPs from the subset of 9 GWAS 
and a set of n=57 SNPs from the full set of 16 GWAS.  
To compute the 3-stage approach GRSs for each ARIC participant, we (1) identified the 
obesity-associated allele for each SNP from the GWAS where that SNP was reported; (2) 
calculated the mean number of risk alleles at each locus; and (3) summed these means across 
loci to produce the 3-stage approach genome-wide scores.  
To compute the top-hits and best-guess approach GRSs, we selected SNPs from the ARIC 
database to match SNPs from 3 published GRSs 
61, 62, 89
 and the full set of obesity-associated 
SNPs listed in the NHGRI GWAS catalog for GWAS of European-descent samples. In cases where 
a specific SNP was not available in the ARIC database, we selected its closest LD proxy. We then 
summed obesity-associated alleles across each set of selected SNPs to create the comparison 
genome-wide scores.  
 To test if the 3-stage approach could construct a GRS that was at least as predictive of 
BMI and obesity as GRSs created with the top-hits and best-guess approaches, we compared 
effect sizes for different GRSs using the ARIC data. All GRSs were standardized to have mean=0 
and standard deviation=1. To measure GRS effect sizes for BMI, we estimated Pearson 
correlations (r) from separate linear regressions of BMI on each of the GRSs. To measure GRS 
effect sizes for obesity, we estimated odds ratios (OR) from separate logistic regressions of 
obesity on each of the GRSs. Regression models were adjusted for age (linear and quadratic 
terms), gender, the age-gender interaction, and the ARIC Study Centers where data were 
collected (hereafter these statistical adjustments are described as “demographics and 
geography”). To test differences between GRS effect sizes, we conducted F-tests (for effect sizes 
estimated from linear regressions) and Wald tests (for effect sizes estimated from logistic 
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regressions). For these tests, models including each of the GRSs being compared were jointly 
estimated using the seemingly unrelated regression method. Seemingly unrelated regression is 
a statistical approach for comparing coefficients from non-nested regression models 
111, 112
. 
Effect sizes were similar for all GRSs. Statistical tests indicated that our 3-stage approach GRSs 
performed as well as or better than GRSs created using top-hits and best-guess approaches 
(Supplementary Table 2.5). Thus, the 3-stage approach produced a GRS that was at least as 
predictive as top-hits and best guess approach GRSs. We used the 3-stage approach GRS created 
from the full set of 16 GWAS (hereafter the “Obesity GRS”) in subsequent analyses. 
Refining the 3-Stage Approach GRS for Obesity. At 7 of the 32 loci identified in the 3-
stage approach analyses of GWAS results (in or near the genes TMEM18, ETV5, BDNF, MTCH2, 
FTO, MC4R, and KCTD15), multiple LD blocks met selection criteria (genome-wide significance or 
replication). To refine the 3-stage approach GRS, we asked whether the genotype for a single 
SNP could be used instead of the mean number of risk alleles at a locus.  First, we identified the 
BMI-increasing allele for each SNP and calculated the linear association between the number of 
BMI-increasing alleles for that SNP and BMI measured at the first ARIC study visit. We next 
compared test statistics and effect sizes between SNPs at each locus to identify the “lead-SNP”, 
the SNP with the strongest association, and the worst-associated SNP. We then compared the 
effect size for the lead-SNP to the effect sizes for the worst-associated SNP and for the mean 
number of risk alleles across SNPs at the locus. These analyses asked 1) whether there was any 
difference in the signal from the different SNPs in a correlated set; and 2) whether a single SNP 
could provide an adequate summary of obesity-associated variation at the locus. Models were 
fitted using linear regression with statistical adjustment for demographics and geography. We 
compared effect sizes using the seemingly unrelated regression method 
111, 112
.  Supplementary 
Table 2.6 shows results from this analysis. At all loci, the lead SNP, worst-associated SNP, and 
mean number of risk alleles performed similarly, with the exception of the FTO locus, at which 
the lead SNP rs9939609 performed slightly better than the worst-associated SNP rs1477196. 
Finally, we tested whether including multiple SNPs at a locus improved the prediction of BMI in 
a regression model. Analyses were conducted using the variable selection algorithm in the Stata 
program mfp 
113
. Details of this method are reported elsewhere 
114
. Briefly, SNPs were added to 
a baseline model predicting BMI as a function of age, sex, and geography in order of decreasing 
statistical significance of the SNPs’ bivariate association with BMI. SNPs were retained in the 
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model if their inclusion resulted in a statistically significant (p<0.05) decrease in model deviance. 
Results showed that model fit was not improved by the inclusion of multiple SNPs at any locus. 
Therefore, we retained only the best-associated SNPs from each of the 7 loci, resulting in a 32-
SNP GRS (Supplementary Table 2.7). 
PART 3. SENSITIVITY ANALYSES TO TEST HETEROGENEITY IN GRS ASSOCIATIONS 
 We tested the linearity of GRS-BMI associations using quadratic and cubic specifications 
of the GRS in linear regression models. Coefficients for the higher order (i.e. squared and cubic) 
GRS terms were not statistically significant (p>0.10 for all), indicating that the GRS-BMI 
association was approximately linear. We tested the measurement specificity of GRS-BMI 
associations by comparing GRS effect sizes for BMI to GRS effect sizes for weight and for waist 
circumference using the seemingly unrelated regression method 
112
. GRS coefficients were 
similar across all three models (p>0.10 for tests of differences), indicating that the GRS predicted 
not just BMI, but related measures of body size and adiposity. We tested the whether GRS-BMI 
associations were different for men and women or for older as compared to younger individuals 
using product terms in linear regression models. Coefficients for product terms were not 
statistically significant (p>0.10 for all), indicating that GRS-BMI associations were similar for men 
and women and for older and younger individuals. Finally, we tested whether GRS-BMI 
associations differed across the 4 in-person assessments in the ARIC Study using the seemingly 
unrelated regression method. GRS effect sizes were similar across all 4 assessments (p>0.10 for 
all comparisons), indicating that GRS-BMI associations were consistent across measurement 
intervals.   
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Supplementary Table 2.1. Genome Wide Association Studies Included In 3-Stage Approach 
Analyses. GWAS information comes from the NHGRI GWAS Catalog (www.genome.gov). Risk 
SNPs were defined as any SNP associated with an obesity-related phenotype (BMI, weight, waist 
circumference, categorical obesity) at p<10
-5
 in the discovery or combined discovery and 
replication samples of the GWAS. *Italicized counts include imputed genotypes; **Lindgren et 
al. also investigated associations with waist circumference, and these are the association tests 
included in the SNP selection analysis; ***Scherag et al. also investigated associations with BMI 
and both phenotypes were included in the SNP selection analysis. Citations for the GWAS are 
included as 
89, 90, 115-129
. 
  
SNPs Phenotypes
Herbert et al. 2006 Affymetrix 86,604 0 Obesity 0
Frayling et al. 2007 Affymetrix 490,032 1 BMI 1
Scuteri et al. 2007 Affymetrix 362,129 1 BMI, Weight 12
Fox et al. 2007 Affymetrix 70,897 5
BMI, Waist 
Circumference
12
Hinney et al. 2007 Affymetrix 440,794 1
Obesity (early onset 
extreme)
15
Liu et al. 2008 Affymetrix 379,319 0 Obesity  3
Loos et al. 2008 Affymetrix 344,883 2 BMI 10
Thorleifsson et al. 2009 Illumina 305,846 18 BMI, Weight 47
Willer et al. 2009
Affymetrix & 
Illumina 
2,399,588 11 BMI 24
Meyre et al. 2009 Illumina 308,846 5 Obesity 32
Cotsapas et al. 2009 Illumina 457,251 13 Obesity (extreme) 15
Lindgren et al. 2009
Affymetrix & 
Illumina 
2,573,738 NA Adiposity** 10
Heard-Costa et al. 2009
Affymetrix & 
Illumina 
512,349 7 Waist Circumference 320
Johansson et al. 2009 Illumina 318,237 17 BMI, Weight 26
Liu et al. 2010 Illumina 559,712 2 BMI 3
Scherag et al. 2010
Affymetrix & 
Illumina 
1,596,878 2
Obesity 
(extreme)***
13
Speliotes et al. 2010
Affymetrix, 
Illumina, 
Perlegen 
~2.8 million 38 BMI 42
SNPs in GWAS CatalogGWAS Chip 
Manufacturer
SNPs 
Genotyped*
Risk SNPs Included in  
Analyses
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Supplementary Table 2.2. Risk SNPs and Source Publications: All SNPs reported as associated 
with Obesity, BMI, Weight, or Waist Circumference at p<1x10
-5
 in Discovery or Combined 
Discovery and Replication Samples 
 
Risk SNP Trait Publication
rs9939609 BMI
Frayling et al. 2007 
Science
rs1121980 BMI
rs6602024 BMI
rs7193144 BMI
rs8050136 BMI
rs9926289 BMI
rs9930506 BMI
rs9939609 BMI
rs9939973 BMI
rs9940128 BMI
rs4512445* Waist Circumference
rs7193144 Waist Circumference
rs8050136 Waist Circumference
rs1106683 BMI
rs1106684 BMI
rs1333026 BMI
rs10488165 Waist Circumference
rs10504576 Waist Circumference
rs1875517 Waist Circumference
rs2206682 Waist Circumference
rs2223662 Waist Circumference
rs4469448 Waist Circumference
rs4471028 Waist Circumference
rs6996971 Waist Circumference
rs953536 Waist Circumference
rs10008032 Extreme Obesity
rs1121980 Extreme Obesity
rs16998603 Extreme Obesity
rs2172478 Extreme Obesity
rs2969001 Extreme Obesity
rs3783950 Extreme Obesity
rs41492957 Extreme Obesity
rs6076920 Extreme Obesity
rs619819 Extreme Obesity
rs7193144 Extreme Obesity
rs8050136 Extreme Obesity
rs9276431 Extreme Obesity
rs9939609 Extreme Obesity
rs9939973 Extreme Obesity
rs9940128 Extreme Obesity
Hinney et al. 2007
Scuteri et al. 2007
Fox et al. 2007
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Supplementary Table 2 Continued
Risk SNP Trait Publication
rs16986921 BMI
rs6013029 BMI
rs6020712 BMI
rs10498767 BMI
rs1121980 BMI
rs17700633 BMI
rs17782313 BMI
rs2572106 BMI
rs2679120 BMI
rs4623795 BMI
rs7212681 BMI
rs7336049 BMI
rs748192 BMI
rs10501087 BMI
rs10783050 BMI
rs10913469 BMI
rs12970134 BMI
rs1776012 BMI
rs2568958 BMI
rs2867125 BMI
rs29941 BMI
rs3101336 BMI
rs3751812 BMI
rs4074134 BMI
rs467650 BMI
rs4788102 BMI
rs4854344 BMI
rs4923461 BMI
rs6265 BMI
rs6499640 BMI
rs7138803 BMI
rs7190492 BMI
rs7336332 BMI
rs7481311 BMI
rs7498665 BMI
rs7561317 BMI
rs7647305 BMI
rs7647305 BMI
rs8044769 BMI
rs8049439 BMI
rs8050136 BMI
rs836964 BMI
rs867559 BMI
rs925946 BMI
rs9424977 BMI
rs1047440 Weight
rs1077393 Weight
rs10835211 Weight
rs1350341 Weight
rs1350341 Weight
rs17069257 Weight
rs1973993 Weight
rs2115172 Weight
rs2260000 Weight
rs2260000 Weight
rs2844479 Weight
rs2844479 Weight
rs3766431 Weight
rs633265 Weight
rs6477693 Weight
Thorleifsson et al. 
2009
Liu et al. 2008
Loos et al. 2008
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Supplementary Table 2 Continued
Risk SNP Trait Publication
rs10769908 BMI
rs10769908 BMI
rs10838738 BMI
rs10838738 BMI
rs10938397 BMI
rs10938397 BMI
rs11084753 BMI
rs11084753 BMI
rs11084753 BMI
rs11773921 BMI
rs12324805 BMI
rs1421085 BMI
rs1439845 BMI
rs17700144 BMI
rs17782313 BMI
rs17782313 BMI
rs2145270 BMI
rs2145270 BMI
rs2245715 BMI
rs2815752 BMI
rs2815752 BMI
rs2815752 BMI
rs4752856 BMI
rs6548238 BMI
rs6548238 BMI
rs6548238 BMI
rs6907460 BMI
rs7181095 BMI
rs7498665 BMI
rs7498665 BMI
rs752238 BMI
rs9931989 BMI
rs9939609 BMI
rs9939609 BMI
rs10508503 Obesity
rs11071927 Obesity
rs11956401 Obesity
rs12588659 Obesity
rs12633433 Obesity
rs1326986 Obesity
rs1343772 Obesity
rs1380100 Obesity
rs1396618 Obesity
rs1421085 Obesity
rs1424233 Obesity
rs16829231 Obesity
rs17782313 Obesity
rs1805081 Obesity
rs1858367 Obesity
rs2011946 Obesity
rs2158044 Obesity
rs2908338 Obesity
rs3026762 Obesity
rs3102841 Obesity
rs413693 Obesity
rs4712652 Obesity
rs4786847 Obesity
rs6463923 Obesity
rs646839 Obesity
rs6580742 Obesity
rs6796959 Obesity
rs7506051 Obesity
rs7717673 Obesity
rs908078 Obesity
rs9275582 Obesity
rs987052 Obesity
Willer et al. 2009 
Meyere et al. 2009 
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Supplementary Table 2 Continued
Risk SNP Trait Publication
rs10433903 Extreme Obesity
rs10999409 Extreme Obesity
rs12295638 Extreme Obesity
rs12492816 Extreme Obesity
rs12635698 Extreme Obesity
rs1435703 Extreme Obesity
rs2274459 Extreme Obesity
rs374748 Extreme Obesity
rs6110577 Extreme Obesity
rs6726292 Extreme Obesity
rs7474896 Extreme Obesity
rs7603514 Extreme Obesity
rs9366829 Extreme Obesity
rs9941349 Extreme Obesity
rs999943 Extreme Obesity
rs10085177 Waist Circumference
rs11970116 Waist Circumference
rs13116494 Waist Circumference
rs2245667 Waist Circumference
rs4737325 Waist Circumference
rs6429082 Waist Circumference
rs7194591 Waist Circumference
rs7826222 Waist Circumference
rs7970350 Waist Circumference
rs987237 Waist Circumference
rs10096750 BMI
rs10145154 BMI
rs10146997 BMI
rs10150332 BMI
rs10173167 BMI
rs10188334 BMI
rs10189761 BMI
rs10190052 BMI
rs10193244 BMI
rs10511835 BMI
rs10813208 BMI
rs10852521 BMI
rs10871777 BMI
rs10875982 BMI
rs10969478 BMI
rs11075985 BMI
rs11075987 BMI
rs11075989 BMI
rs11075990 BMI
rs11127483 BMI
rs11127484 BMI
rs11127485 BMI
rs11127491 BMI
rs11152213 BMI
rs11169176 BMI
rs1121980 BMI
rs11520442 BMI
rs11642841 BMI
rs11660783 BMI
rs11662368 BMI
rs11663816 BMI
rs11664883 BMI
rs11665563 BMI
rs12002080 BMI
rs12149832 BMI
rs12446228 BMI
rs12623218 BMI
rs12714414 BMI
rs12714415 BMI
rs12954782 BMI
rs12955983 BMI
rs12957347 BMI
rs12960928 BMI
rs12964203 BMI
Heard-Costa et al. 
2009 
Lindgren et al. 2009 
Cotsapas et al. 2009 
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Supplementary Table 2 Continued
Risk SNP Trait Publication
rs12966550 BMI
rs12967135 BMI
rs12969709 BMI
rs12970134 BMI
rs12992154 BMI
rs12995480 BMI
rs13007080 BMI
rs13007086 BMI
rs13012571 BMI
rs13021737 BMI
rs1320330 BMI
rs1320331 BMI
rs1320336 BMI
rs1320337 BMI
rs1320338 BMI
rs13386517 BMI
rs13386627 BMI
rs13386964 BMI
rs13388043 BMI
rs13393304 BMI
rs13396935 BMI
rs13397165 BMI
rs13401686 BMI
rs13415094 BMI
rs1350341 BMI
rs1421085 BMI
rs1456404 BMI
rs1457489 BMI
rs1477196 BMI
rs1539952 BMI
rs1553754 BMI
rs1555967 BMI
rs1558902 BMI
rs1619975 BMI
rs1673518 BMI
rs17109256 BMI
rs17175643 BMI
rs17201502 BMI
rs17299673 BMI
rs17700144 BMI
rs17782313 BMI
rs17817288 BMI
rs17817449 BMI
rs17817964 BMI
rs1861866 BMI
rs1861867 BMI
rs1942860 BMI
rs1942863 BMI
rs1942866 BMI
rs2051311 BMI
rs2051312 BMI
rs2058908 BMI
rs2168708 BMI
rs2168711 BMI
rs2206277 BMI
rs2288278 BMI
rs2331841 BMI
rs2397026 BMI
rs2860323 BMI
rs2867108 BMI
rs2867109 BMI
rs2867110 BMI
rs2867112 BMI
rs2867113 BMI
rs2867122 BMI
rs2867123 BMI
rs2867125 BMI
rs2867131 BMI
rs2903492 BMI
Heard-Costa et al. 
2009 
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Supplementary Table 2 Continued
Risk SNP Trait Publication
rs2947411 BMI
rs297924 BMI
rs34341 BMI
rs3751812 BMI
rs3751813 BMI
rs3928247 BMI
rs4045166 BMI
rs4299252 BMI
rs4423631 BMI
rs4438957 BMI
rs4452188 BMI
rs4613321 BMI
rs4615388 BMI
rs4620360 BMI
rs474112 BMI
rs475134 BMI
rs476828 BMI
rs4783819 BMI
rs4784323 BMI
rs4793927 BMI
rs4854344 BMI
rs4854348 BMI
rs4854349 BMI
rs487720 BMI
rs489693 BMI
rs492443 BMI
rs497353 BMI
rs5017300 BMI
rs5017303 BMI
rs521663 BMI
rs523288 BMI
rs536783 BMI
rs538656 BMI
rs545708 BMI
rs559623 BMI
rs562622 BMI
rs563726 BMI
rs565239 BMI
rs565970 BMI
rs571312 BMI
rs574988 BMI
rs589850 BMI
rs590215 BMI
rs591166 BMI
rs611428 BMI
rs633265 BMI
rs649721 BMI
rs6499640 BMI
rs6548237 BMI
rs6567155 BMI
rs6567160 BMI
rs6567161 BMI
rs663129 BMI
rs666181 BMI
rs6711012 BMI
rs6719518 BMI
rs6719980 BMI
rs6725549 BMI
rs6728726 BMI
rs6731348 BMI
rs6731688 BMI
rs6732471 BMI
rs6734363 BMI
rs6742576 BMI
rs6743060 BMI
rs6744646 BMI
rs6744653 BMI
rs6745266 BMI
rs6752470 BMI
Heard-Costa et al. 
2009 
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Supplementary Table 2 Continued
Risk SNP Trait Publication
rs6755502 BMI
rs681630 BMI
rs682614 BMI
rs683430 BMI
rs7022642 BMI
rs7132908 BMI
rs7138803 BMI
rs7144011 BMI
rs7185735 BMI
rs7190492 BMI
rs7193144 BMI
rs7201850 BMI
rs7202116 BMI
rs7203521 BMI
rs7205986 BMI
rs7206010 BMI
rs7206790 BMI
rs7240566 BMI
rs7338657 BMI
rs7561317 BMI
rs7567570 BMI
rs7570198 BMI
rs7571957 BMI
rs7574359 BMI
rs7576624 BMI
rs7576635 BMI
rs7585056 BMI
rs7587786 BMI
rs7604609 BMI
rs7608050 BMI
rs7715806 BMI
rs7831920 BMI
rs8043757 BMI
rs8044769 BMI
rs8047395 BMI
rs8050136 BMI
rs8051591 BMI
rs8055197 BMI
rs8057044 BMI
rs8083289 BMI
rs8086627 BMI
rs8089364 BMI
rs8091524 BMI
rs8095404 BMI
rs921971 BMI
rs939582 BMI
rs939583 BMI
rs953442 BMI
rs975918 BMI
rs981106 BMI
rs981113 BMI
rs987237 BMI
rs9922047 BMI
rs9922619 BMI
rs9922708 BMI
rs9923147 BMI
rs9923233 BMI
rs9923544 BMI
rs9928094 BMI
rs9930333 BMI
rs9930501 BMI
rs9930506 BMI
rs9931494 BMI
rs9932754 BMI
rs9935401 BMI
rs9936385 BMI
rs9937053 BMI
Heard-Costa et al. 
2009 
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Supplementary Table 2 Continued
Risk SNP Trait Publication
rs993887 BMI
rs9939609 BMI
rs9939973 BMI
rs9940128 BMI
rs9940646 BMI
rs9941349 BMI
rs10059683 Waist Circumference
rs10066756 Waist Circumference
rs10068332 Waist Circumference
rs10146690 Waist Circumference
rs10150482 Waist Circumference
rs10869557 Waist Circumference
rs10869558 Waist Circumference
rs10869559 Waist Circumference
rs11778132 Waist Circumference
rs11780082 Waist Circumference
rs11857639 Waist Circumference
rs11990688 Waist Circumference
rs12271537 Waist Circumference
rs12274672 Waist Circumference
rs12475139 Waist Circumference
rs12792768 Waist Circumference
rs13404551 Waist Circumference
rs1447905 Waist Circumference
rs1521252 Waist Circumference
rs16930931 Waist Circumference
rs17008958 Waist Circumference
rs17061143 Waist Circumference
rs17109221 Waist Circumference
rs17476669 Waist Circumference
rs17537900 Waist Circumference
rs17836088 Waist Circumference
rs2164210 Waist Circumference
rs2236783 Waist Circumference
rs2322659 Waist Circumference
rs2322660 Waist Circumference
rs2365642 Waist Circumference
rs2370982 Waist Circumference
rs303211 Waist Circumference
rs309134 Waist Circumference
rs309137 Waist Circumference
rs309160 Waist Circumference
rs309168 Waist Circumference
rs4098360 Waist Circumference
rs4420638 Waist Circumference
rs4701252 Waist Circumference
rs4758213 Waist Circumference
rs4758215 Waist Circumference
rs507824 Waist Circumference
rs569406 Waist Circumference
rs6499641 Waist Circumference
rs6714750 Waist Circumference
rs6716536 Waist Circumference
rs6754311 Waist Circumference
rs6817633 Waist Circumference
rs6837818 Waist Circumference
rs6870971 Waist Circumference
rs687670 Waist Circumference
rs693895 Waist Circumference
rs6998794 Waist Circumference
rs7110070 Waist Circumference
rs7156625 Waist Circumference
rs745500 Waist Circumference
rs748841 Waist Circumference
rs7579771 Waist Circumference
rs7824886 Waist Circumference
rs7932813 Waist Circumference
rs8059991 Waist Circumference
rs892715 Waist Circumference
rs9598518 Waist Circumference
rs9790104 Waist Circumference
Heard-Costa et al. 
2009 
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Supplementary Table 2 Continued
Risk SNP Trait Publication
rs1024889 BMI
rs1152846 BMI
rs12517906 BMI
rs1458095 BMI
rs1878047 BMI
rs1927702 BMI
rs2383393 BMI
rs3803915 BMI
rs3803915 BMI
rs3934834 BMI
rs4085400 BMI
rs824931 BMI
rs875283 BMI
rs10844154 Weight
rs10972341 Weight
rs10972350 Weight
rs1152846 Weight
rs12517906 Weight
rs1570885 Weight
rs1816002 Weight
rs1840440 Weight
rs2765086 Weight
rs4879869 Weight
rs7209395 Weight
rs7919006 Weight
rs965178 Weight
rs2275215 BMI
rs10458787 BMI
rs11127485 BMI
rs1558902 BMI
rs9935401 BMI
rs10926984 Obesity
rs12145833 Obesity
rs2783963 Obesity
rs11127485 Obesity
rs17150703 Obesity
rs13278851 Obesity
rs516175 Obesity
rs1558902 Obesity
rs9935401 Obesity
rs17700144** Obesity
Liu et al. 2010 
Scherag et al. 2010 
Johansson et al. 2009
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Supplementary Table 2.2 Footnote: *Reported as "SNP_A-2284869" and crosswalked to rs ID 
using the Affy 6.0 SNP name to rs ID crosswalk file "GenomeWideSNP_6.na30.annot.csv"; **The 
GWAS catalog reports rs10871777 (in LD with rs17700144 at R
2
=0.85) as the obesity-associated 
SNP near the gene MC4R in Scherag et al. SNPs are reported only once per GWAS. Associations 
are reported for BMI where present and for other phenotypes where BMI was not investigated 
or the SNP was not associated with BMI at p<1 x10
-5
 
  
Supplementary Table 2 Continued
Risk SNP Trait Publication
rs1558902 BMI
rs2860323 BMI
rs6567160 BMI
rs10938397 BMI
rs10767664 BMI
rs543874 BMI
rs2815752 BMI
rs10182181 BMI
rs12444979 BMI
rs7498665 BMI
rs987237 BMI
rs2241423 BMI
rs9816226 BMI
rs7138803 BMI
rs2287019 BMI
rs1514177 BMI
rs13107325 BMI
rs2112347 BMI
rs10968576 BMI
rs3817334 BMI
rs3810291 BMI
rs887912 BMI
rs10150332 BMI
rs7640855 BMI
rs11847697 BMI
rs2890652 BMI
rs11165643 BMI
rs4771122 BMI
rs4836133 BMI
rs4929949 BMI
rs29938 BMI
rs9296115 BMI
rs2922763 BMI
rs2444217 BMI
rs867559 BMI
rs3764400 BMI
rs255414 BMI
rs6955651 BMI
rs17016663 BMI
rs6477694 BMI
rs2652594 BMI
rs2035935 BMI
Speliotes et al. 2010 
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Supplementary Table 2.3. Replicated and/or Genome-Wide Significant LD Blocks Identified in 
3-Stage Approach Analyses. LD blocks were defined from LD analyses of risk SNPs (genotype-
phenotype association at p<1x10
-5
) using data from the HapMap version 3 CEU sample accessed 
via Seattle SNPs's Genome Variation Server and an LD threshold of R
2
≥0.95. Replication was 
evaluated as the number of GWAS reporting any SNP in the block as a risk SNP. Genes were 
evaluated within 100kb in either direction from an LD block's outermost SNPs. 
 
Chromsome
Identified 
LD Blocks
Replicated 
LD Blocks
Mean 
Number of 
Replications 
(All Blocks) Genes
1 4 3 2.0 NEGR1, TNNI3K, PTB2, SEC16B
2 6 2 2.0 LRP1B, TMEM18
3 3 0 1.0 CADM2, ETV5/DGKG
4 2 1 1.5 GNPDA2, SLC39A8
5 2 0 1.0 POC5, ZNF608
6 1 1 3.0 TFAP2B
9 2 1 1.5 LING02/LRRN6C, LMX1B
11 7 0 1.0 RPL27A, BDNF, MTCH2
12 1 1 3.0 BDCDIN3D/FAIM2/NCKAP5L
13 1 0 3.0 MTIF3, GRF3A
14 2 1 1.5 PRKD1, NRXN3
15 1 0 1.0 MAP2K5
16 26 14 3.0 GRP5B, ATXN2L/TUFM/SH2B1, FTO
18 7 7 2.6 MC4R
19 4 1 1.3 KCTD15, ZC3H4, QPCTL, TMEM160
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Supplementary Table 2.4. Characteristics of Replicated and/or Genome-Wide Significant LD 
Blocks
Chrom-
osome
Chromosomal Space Covered 
by All Risk SNPs in the LD 
Block (NCBI Build 36) Nearby Genes
Seed SNPs (risk SNPs in LD with all risk SNPs in 
block at R
2
≥0.95) // Proxy SNPs (risk SNPs in LD 
with any seed SNP at R2≥0.95)
Any SNP in 
Block Genome-
Wide 
Significant [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16]
72,523,773 - 72,585,028 NEGR1 rs2568958, rs2815752, rs3101336 Yes X X X
74,763,990 TNNI3K rs1514177 Yes X
96,696,685 - 96,716,582 PTBP2 rs11165643 // rs1973993 Yes X X
176,156,103 - 176,180,142 SEC16B rs10913469, rs543874 Yes X X
604,168 - 643,874 TMEM18 Yes X X X X
604,210 - 643,874 TMEM18 Yes X X X X
624,905 TMEM18 rs6548238 Yes X
25,003,800 rs10182181 Yes X
59,156,381 rs887912 Yes X
142,676,401 LRP1B rs2890652 Yes X
85,956,854 CADM2 rs7640855 Yes X
187,316,984 ETV5/DGKG rs7647305 Yes X
187,317,193 ETV5/DGKG rs9816226 Yes X
44,877,284 rs10938397 Yes X X
103,407,732 SLC39A8 rs13107325 Yes X
75,050,998 POC5 rs2112347 Yes X
124,360,002 rs4836133 Yes X
6 50,906,485 - 50,911,009 TFAP2B rs2206277, rs987237 Yes X X X
28,404,339 LING02 rs10968576 Yes X
128,505,146 LMX1B rs867559 p<1x10
-6
X X
8,561,169 STK33 rs4929949 Yes X
27,603,861 - 27,626,684 BDNF rs10501087, rs4074134, rs4923461 Yes X
27,636,492 BDNF rs6265 Yes X
27,682,562 BDNF rs10767664 Yes X
27,623,778 - 27,623,778 BDNF rs925946 Yes X
47,604,618 - 47,619,625 MTCH2 rs10838738, rs4752856 Yes X
47,607,569 MTCH2 rs3817334 Yes X
12
48,533,735
BDCDIN3D, FAIM2, 
NCKAP5L rs7138803 Yes X X X
13 26,918,180 MTIF3, GRF3A rs4771122 Yes X
29,584,863 rs11847697 Yes  X
78,961,635 - 79,014,915 NRXN3
rs10145154, rs10150332, rs17109256, 
rs7144011 // rs10146997, rs10150482, 
rs17109221,  rs17836088, rs7156625 Yes X X
15 65,873,892 MAP2K5 rs2241423 Yes X
GWAS Publication
5
9
11
14
1
2
See footnote
3
4
LD Block
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Supplementary Table 4 Continued
Chrom-
osome
Chromosomal Space Covered 
by All Risk SNPs in the LD 
Block (NCBI Build 36)
Genes Overlapping LD 
Block/ 10kb of SNP*
Seed SNPs (risk SNPs in LD with all risk SNPs in 
block at R
2
≥0.95) // Proxy SNPs (risk SNPs in LD 
with any seed SNP at R2≥0.95)
Any SNP in 
Block Genome-
Wide 
Significant [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16]
19,841,101 GPRC5B rs12444979 Yes X
28,745,016 - 28,790,742 ATXN2L, TUFM, SH2B1 rs4788102, rs7498665, rs8049439 Yes X X X
52,312,678 - 52,327,178 FTO rs6499640, rs7203521, rs7206010 Yes X X
52,355,409 FTO rs7206790 Yes X
52,356,024 - 52,361,841 FTO rs8047395 //rs1861866, rs8055197 Yes X
52,356,024 - 52,363,781 FTO
rs1861866, rs8055197 // rs10852521, 
rs8047395, rs9922047 Yes X
52,360,657 - 52,372,662 FTO
rs10852521, rs9922047 // rs11075987, 
rs1861866, rs8055197 Yes X
52,362,466 - 52,372,662 FTO rs11075987 // rs10852521, rs9922047 Yes X
52,365,265 FTO rs17817288 Yes X
52,370,115 FTO rs8057044 Yes X
52,396,636 FTO rs8044769 Yes X X
52,357,008 - 52,366,748 FTO
rs11075985, rs9940646 // rs1121980, 
rs9923147, rs9923544, rs9928094, rs9930333, 
rs9937053, rs9939973, rs9940128 Yes X X X X
52,357,008 - 52,384,680 FTO
rs1121980, rs9923147, rs9923544, rs9928094, 
rs9930333, rs9937053, rs9939973, rs9940128 
// 
rs11075985, rs1421085, rs1558902, 
rs7201850,  rs9931494, rs9940646, rs9941349 Yes X X X X X X X X X
52,357,008 - 52,385,567 FTO rs1421085, rs1558902 // rs17817964, 
rs7185735, rs7193144, rs7202116, rs9937053 Yes X X X X X X X
52,357,008 - 52,389,272 FTO
rs7201850, rs9931494, rs9941349 // 
rs1121980, rs9922619, rs9922708, rs9923147, 
rs9923544, rs9928094, rs9930333, rs9930501, 
rs9930506, rs9932754, rs9937053, rs9939973, 
rs9940128 Yes X X X X X
52,358,455 - 52,400,409 FTO
rs17817964, rs7185735 // rs11075989, 
rs11075990, rs12149832, rs1421085, 
rs1558902, rs17817449,  rs3751812, 
rs7193144, rs7202116, rs8043757, rs8050136, 
rs8051591, rs9923233, rs9935401, rs9939609 Yes X X X X X X X X X
52,361,075 - 52,400,409 FTO
rs7193144, rs7202116 // rs11075989, 
rs11075990, rs12149832, rs1558902, 
rs17817449, rs17817964, rs3751812, 
rs7185735, rs8043757, rs8050136, rs8051591, 
rs9923233, rs9935401, rs9939609 Yes X X X X X X X X
52,368,187 - 52,385,567 FTO
rs11075989, rs11075990, rs17817449, 
rs3751812, rs8043757, rs8050136, rs8051591, 
rs9923233, rs9935401, rs9939609 // 
rs17817964, rs7185735, rs7193144, 
rs7202116, rs9936385 Yes X X X X X X X
52,368,187 - 52,400,409 FTO rs12149832 // rs17817964, rs7185735, 
rs7193144, rs7202116 Yes X X X
52,376,670 - 52,377,378 FTO rs9936385 // rs11075989, rs9923233 Yes X
52,379,363 - 52,389,272 FTO
rs9922619, rs9922708, rs9930501, rs9932754 
// rs7201850,  rs9930506, rs9931494, 
rs9941349 Yes X X X
52,382,989 - 52,389,272 FTO rs9930506 // rs9922619, rs9922708, 
rs9930501, rs9931494, rs9932754, rs9941349 Yes X X X
52,406,062 FTO rs1861867 Yes X
52,357,888 - 52,386,253 FTO
rs12446228, rs1477196, rs4783819, rs7190492 Yes X X
52,376,209 FTO rs3751813 Yes X
52,402,988 FTO rs11642841 Yes X
GWAS Publication
16
LD Block
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Supplementary Table 2.4 Footnote: GWAS are numbered as follows: [1] Frayling et al. 2007, 
Science; [2] Scuteri et al. 2007, PLoS Genetics; [3] Fox et al. 2007, BMC Medical Genetics; [4] 
Hinney et al. 2007, PLoS One; [5] Liu et al. 2008, Human Molecular Genetics; [6] Loos et al. 2008, 
Nature Genetics; [7] Thorleifsson et al. 2009, Nature Genetics; [8] Willer et al. 2009, Nature 
Genetics; [9] Meyere et al. 2009 Nature Genetics; [10] Cotsapas et al. 2009, Human Molecular 
Genetics; [11] Lindgren et al. 2009 PLoS Genetics; [12] Heard-Costa et al. 2009, PLoS Genetics; 
[13] Johansson et al. 2009, Obesity; [14] Liu et al. 2010, Twin Research and Human Genetics; [15] 
Shcerag et al. 2010, PLoS Genetics; Speliotes et al. 2010, Nature Genetics. LD Blocks were 
defined using an R
2
 threshold of 0.95. Genes are reported within 100 kb of any seed SNP. 
Italicized genes fall outside the 100kb range, but contain SNPs in LD with a block seed. GWAS are 
indicated as replicating a block if they reported a SNP in LD at R
2
≥0.95 with a block seed or proxy 
as associated with an obesity-related phenotype at p<1x10
-5
 in either their discovery or 
combined discovery and replication samples. 
Block 2.2: (seeds) rs10173167, rs10188334, rs10189761, rs10190052, rs10193244, rs11127484, 
rs11127485, rs11127491, rs12714414, rs12714415, rs12992154, rs12995480, rs13007080, 
Supplementary Table 4 Continued
Chrom-
osome
Chromosomal Space Covered 
by All Risk SNPs in the LD 
Block (NCBI Build 36)
Genes Overlapping LD 
Block/ 10kb of SNP*
Seed SNPs (risk SNPs in LD with all risk SNPs in 
block at R
2
≥0.95) // Proxy SNPs (risk SNPs in LD 
with any seed SNP at R2≥0.95)
Any SNP in 
Block Genome-
Wide 
Significant [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16]
55,962,962 MC4R rs17700144 p<1x10
-6
X X X
55,980,115 - 56,003,928 MC4R
rs10871777, rs11152213, rs12967135, 
rs17782313, rs2168711, rs476828, rs523288, 
rs538656, rs571312, rs6567160, rs663129 Yes X X X X X
55,964,628 - 56,003,732 MC4R
rs1350341, rs1619975, rs1673518, rs2051311, 
rs2051312, rs2331841, rs474112, rs475134, 
rs487720, rs536783, rs545708, rs559623, 
rs562622, rs565239, rs565970, rs574988, 
rs589850, rs591166, rs611428, rs649721, 
rs6567161, rs666181, rs681630, rs682614, 
rs683430, rs975918, rs993887 // rs521663,  
rs633265 p<1x10
-6
X X
56,009,782 - 56,048,783 MC4R
rs12960928 // rs11663816, rs11664883, 
rs11665563, rs12954782, rs12969709, 
rs12970134, rs1457489, rs17175643, 
rs492443, rs8083289, rs8089364, rs921971 Yes X X
56,009,782 - 56,062,310 MC4R
rs921971 // rs11663816, rs11664883, 
rs11665563, rs12954782, rs12955983, 
rs12960928, rs12964203, rs12966550, 
rs12969709, rs12970134, rs1457489, 
rs17175643, rs2168708, rs492443, rs8083289, 
rs8089364 Yes X X
56,009,809 - 56,047,722 MC4R
rs12955983 // rs11663816, rs11664883, 
rs11665563, rs12954782,  rs12969709, 
rs12970134, rs1457489, rs17175643, 
rs8083289, rs8089364, rs921971 Yes X X
56,009,809 - 56,062,310 MC4R
rs11663816, rs11664883, rs11665563, 
rs12954782, rs12964203, rs12966550, 
rs12969709, rs12970134, rs1457489, 
rs17175643, rs2168708, rs8083289, rs8089364 
// rs12955983, rs12960928,  rs921971 Yes X X
39,001,372 - 39,003,321 KCTD15 rs29938, rs29941 Yes X X
39,013,977 KCTD15 rs11084753 Yes X
52,260,843 ZC3H4, TMEM160 rs3810291 Yes X
50,894,012 QPCTL rs2287019 Yes X
LD Block GWAS Publication
19
18
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rs13007086, rs13012571, rs13021737, rs1320331, rs1320336, rs1320337, rs1320338, 
rs13386517, rs13386627, rs13386964, rs13388043, rs13393304, rs13396935, rs13397165, 
rs13401686, rs13415094, rs2860323, rs2867108, rs2867109, rs2867110, rs2867112, rs2867113, 
rs2867122, rs2867125, rs2903492, rs2947411, rs4423631, rs4452188, rs4613321, rs4854344, 
rs4854348, rs4854349, rs5017300, rs5017303, rs6711012, rs6719518, rs6719980, rs6725549, 
rs6728726, rs6731348, rs6731688, rs6732471, rs6734363, rs6743060, rs6744646, rs6744653, 
rs6752470, rs6755502, rs7561317, rs7567570, rs7570198, rs7571957, rs7574359, rs7576624, 
rs7576635, rs7585056, rs7604609, rs7608050, rs939582, rs939583 
 
Block 2.3: (seeds) rs2867123, (proxies) rs10173167, rs10188334, rs10189761, rs10190052, 
rs10193244, rs11127484, rs11127485, rs11127491, rs12714414, rs12714415, rs12992154, 
rs12995480, rs13007080, rs13007086, rs13012571, rs13021737, rs1320331, rs1320336, 
rs1320337, rs1320338, rs13386517, rs13386627, rs13386964, rs13388043, rs13393304, 
rs13396935, rs13397165, rs13401686, rs13415094, rs2860323, rs2867108, rs2867109, 
rs2867110, rs2867112, rs2867113, rs2867122, rs2867123, rs2867125, rs2903492, rs4423631, 
rs4452188, rs4613321, rs4854344, rs4854348, rs4854349, rs5017300, rs5017303, rs6711012, 
rs6719518, rs6719980, rs6725549, rs6728726, rs6731348, rs6731688, rs6732471, rs6734363, 
rs6743060, rs6744646, rs6744653, rs6752470, rs6755502, rs7561317, rs7567570, rs7570198, 
rs7571957, rs7574359, rs7576624, rs7576635, rs7585056, rs7604609, rs7608050, rs939582, 
rs939583 
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Supplementary Table 2.5. Effect Sizes for Genetic Risk Scores Created Using the 3-Stage 
Approach and the Best-Guess and Top-Hits Approaches. To measure BMI effect sizes for the 
GRSs, we estimated Pearson correlations ( r ) from separate linear regressions of BMI on each of 
the GRSs. To measure obesity effect sizes for the GRSs, we estimated odds ratios (OR) from 
separate logistic regressions of obesity on each of the GRSs. Regression models were adjusted 
for age (linear and quadratic terms), gender, the age-gender interaction, and the ARIC Study 
Centers where data were collected. In Panel A, the Best-Guess GRS was based on the GRS 
published by Li and colleagues 
62
 and the Top-Hits GRS was based on the GRS published by 
Peterson and colleagues 
61
. In Panel B, the Best Guess GRS was based on the full set of obesity- 
and BMI-associated SNPs listed in the NHGRI GWAS Catalog and the Top-Hits GRS was based on 
the GRS published by Speliotes and colleagues 
89
. ***p<0.001. Comparison of effect sizes using 
the seemingly unrelated regression method 
112
 indicated that effect sizes for the 3 GRSs in Panel 
A were not statistically different from one another (p-value for difference >0.10 for all), but that 
among the GRSs in Panel B, the 3-stage approach performed better than the Best-Guess and 
Top-Hits GRSs (p<0.05 for all).  However, our sample had only 40% power to detect effect size 
differences of r=0.01 / OR=1.01, so this result should be interpreted with caution. 
  
  
BMI Obesity
Approach to GRS 
Construction SNPs
Pearson Correlation 
( r )
Odds Ratio                
[95% CI]
3-Stage 28 0.08*** 1.08 [1.06-1.10]
Best-Guess 12 0.08*** 1.08 [1.06-1.11]
Top-Hits 59 0.06*** 1.07 [1.04-1.09]
3-Stage 57 0.11*** 1.12 [1.10-1.15]
Best-Guess 97 0.10*** 1.11 [1.09-1.13]
Top-Hits 32 0.10*** 1.10 [1.08-1.12]
Panel A. GRSs Constructed from Results of 9 GWAS Published by 
December 31, 2008
Panel B. GRSs Constructed from Results of the Full Set of 16 GWAS
Effect Sizes
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Supplementary Table 2.6. Analysis of Loci with Multiple Tag SNPs. * "Lead SNP" is underlined; 
"Worst-associated SNP" is italicized; Test statistics and effect sizes were estimated in linear 
regression models of BMI adjusted for demographics and geography. "Lead SNPs" and "Worst-
associated SNPs" were determined from the test statistics for the individual SNPs. Effect sizes 
were compared using the seemingly unrelated regressions method 
112
.   
 
Lead SNP
Worst-Associated 
SNP
Mean Number of 
BMI-Increasing 
Alleles
0.027 0.023 0.025
p=0.276 p=0.371
0.007 <0.001 0.018
p=0.721 p=0.427
0.027 0.022 0.026
p=0.124 p=0.485
0.020 0.019 0.020
p=0.871 p=0.878
0.072 0.034 0.068
p<0.001 p=0.104
0.026 0.019 0.025
p=0.158 p=0.062
0.010 0.009 0.009
p=0.879 p=0.913
Effect Size (Pearson's r)                                                                         
p-value for comparison with lead SNP
Locus
Chr 2 TMEM18
ARIC SNPs Tagging LD 
Blocks in Genic Region
Chr 11 MTCH
Chr 11 BDNF
Chr 16 FTO
rs1477196 , rs17817288, 
rs1121980, rs9922047, 
rs9939973, rs9940128, 
rs9941349, rs7193144, 
rs7203521, rs9939609, 
rs8050136, rs9930506
Minimum R
2  
Among Tag 
SNPs
0.86
0.77
0.40
rs10189761 , rs2867123,  
rs4854345
0.94
rs12419692, rs3817334
rs10501087, rs7103411 , 
rs6265, rs11030108
0.85
rs12516728, rs9863591
Chr 3 ETV5/DGKG
rs476828 , rs1673518, 
rs17782313, rs11663816, 
rs11665563, rs12969709, 
rs12970134
rs29942 , rs11084753 0.58Chr 19 KCDT15
Chr 18 MC4R 0.25
  
 
 
 
  
 
 
 
Supplementary Table 2.7. SNPs Included in the Obesity Genetic Risk Score.   
 
 
Chr Nearby Gene Tag SNP
GWAS 
Replications
BMI-Increasing 
Allele in GWAS 
Test 
Alelle 
Other 
Allele
Effect-
Size 
Weight
Test Allele 
Frequency
Per Allele 
Change in BMI p-value
Direction of 
Association 
Inconsistent 
with GWAS
Test Allele 
Frequency
Per Allele 
Change in BMI p-value
Direction of 
Association 
Inconsistent 
with GWAS
NEGR1 rs2815752 3 Major G A 0.13 38% -0.259 0.001 45% -0.071 0.673
TNNI3K rs1514175 1 Minor A G 0.07 43% -0.001 0.985 68% -0.091 0.608 X
PTBP2 rs1555543 2 Major A C 0.06 42% -0.128 0.086 57% -0.031 0.855
SEC16B rs543874 2 Minor G A 0.22 20% 0.341 0.000 25% 0.335 0.095
FANCL rs759250 1 Minor A G 0.10 29% 0.036 0.656 8% -0.242 0.475 X
LRP1B rs2121279 1 Minor T C 0.08 14% 0.234 0.032 3% -0.253 0.651 X
TMEM18 rs2867123 5 Major G C 0.30 17% -0.237 0.018 12% 0.022 0.935 X
RBJ rs10182181 1 Minor G A 0.14 46% 0.117 0.117 84% 0.758 0.001
CADM2 rs12714640 1 Minor A C 0.10 19% 0.278 0.003 6% 0.006 0.987
ETV5/DGKG rs1516728 2 Major T A 0.11 23% -0.060 0.489 52% -0.098 0.565
GNPDA2 rs12641981 2 Minor T C 0.18 43% 0.088 0.238 23% 0.103 0.602
SLC39A8 rs13114738 1 Minor T C 0.13 8% 0.506 4.15E-04 1% -1.583 0.008 X
POC5 FLJ35779 rs10057967 1 Major C T 0.10 37% -0.227 0.003 49% 0.128 0.435 X
ZNF608 rs6864049 1 Minor G A 0.07 46% -0.189 0.012 X 19% -0.463 0.033 X
6 TFAP2B rs734597 3 Minor A G 0.13 17% 0.382 1.21E-04 9% 0.030 0.920
LING02 LRRN6C rs1412235 1 Minor C G 0.11 31% 0.003 0.970 16% 0.365 0.111
LMX1B rs867559 2 Minor G A 0.24 20% 0.088 0.339 32% 0.025 0.889
RPL27A rs2028882 1 Major C A 0.06 50% -0.065 0.375 66% 0.116 0.515 X
BDNF rs10501087 2 Major C T 0.18 21% -0.223 0.013 7% -0.521 0.181
MTCH2 rs12419692 2 Minor A C 0.05 36% 0.146 0.059 9% 0.012 0.968
12 BDCDIN3D, FAIM2 rs7138803 3 Minor A G 0.12 38% 0.164 0.033 17% 0.100 0.650
13 MTIF3, GRF3A rs1475219 1 Minor C T 0.09 21% 0.262 0.004 22% -0.099 0.632 X
PRKD1 rs1440983 1 Minor A G 0.15 5% 0.266 0.129 23% 0.156 0.449
NRXN3 rs7144011 2 Minor T G 0.13 22% 0.165 0.064 24% 0.164 0.428
15 MAP2K5 rs28670272 1 Major G A 0.13 23% -0.212 0.014 41% 0.005 0.977 X
GPR5B rs11639988 1 Major G A 0.17 15% 0.006 0.952 X 24% -0.262 0.194
ATXN2L, TUFM, SH2B1 rs12443881 3 Minor T C 0.15 39% -0.005 0.948 X 9% -0.607 0.030 X
FTO rs9939609 11 Minor A T 0.38 41% 0.496 8.19E-11 48% 0.129 0.443
18 MC4R rs12970134 6 Minor A G 0.21 26% 0.209 0.012 13% 0.057 0.822
KCTD15 rs11084753 3 Major A G 0.04 33% -0.071 0.371 36% 0.197 0.270 X
QPCTL rs11083779 1 Major C T 0.07 4% -0.227 0.196 11% -0.267 0.294
ZC3H4 TMEM160 rs7250850 1 Major G C 0.09 29% -0.174 0.032 80% -0.343 0.124
9
5
4
3
2
1
White Participants, n=8,210-8,8,286 Black Participants, n=2,402-2,442
14
11
19
16
9
0
 
  
 
 
 
  
 
Supplementary Table 2.7 Footnote: GWAS replications include GWAS reporting any SNP in any LD block tagged by the SNP as obesity-
associated at p<1x10
-5
 in the discovery or combined discovery and replication samples. Test allele and other allele are reported from the 
positive strand. Effect-size weights were obtained from 
89
 for all SNPs with the exception of rs867559, for which the effect size weight 
was obtained from 
90
. Allele frequencies and per-allele effects are reported based on all participants in the analysis sample. Per-allele 
effects were estimated from linear regressions of BMI on SNP genotype (number of minor alleles), adjusted for demographics and 
geography. P-values are reported based on heteroskedasticity robust standard errors. 
9
1
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Supplementary Table 2.8. Educational Attainment of White and African American ARIC 
Participants. Educational attainment was ascertained via self-report at the first ARIC visit. 
Distributions of BMI-increasing alleles for the 32 obesity GRS SNPs were comparable across 
educational strata in African Americans and whites (p>0.10 for all comparisons).   
 
 
 
 
 
 
Highest Level of Schooling
None/ Grade School 5% 19%
Some High School 11% 21%
High School Graduate 36% 22%
Vocational School 9% 7%
College 30% 18%
Graduate/ Professional School 9% 14%
Percent of  Visit 1 Sample
  
 
 
 
 
 
Supplementary Table 2.9. Predictiveness of Model-Based Risk Scores With and Without The Obesity Genetic Risk Score. (m1-5) denote 
separate models used to estimate risk scores for BMI and obesity. Risk scores were predicted values from linear regression of BMI and 
predicted probabilities from probit regressions of obesity. The first model, m1, includes measures of  age, sex, and ARIC Study Center 
where data were collected. The regression model was specified to include linear and quadratic terms for age and a product term 
modeling interaction between age and sex. The simple genetic risk assessment (SNPs in FTO and downstream of MC4R) is a component 
of the weighted obesity genomic risk score. Thus, model m3 contains all of the information in model m2 as well as information from the 
remaining 30 SNPs included in the GRS. The 5 categories of socioeconomic status were modeled as dichotomous variables and were 
allowed to vary by sex in their relationship with obesity and BMI. Values of R
2
 were estimated using linear regression models adjusted 
for demographic and geographic information. Percentile-based confidence intervals were generated using the bootstrap method. AUCs 
and percentile-based confidence intervals were estimated from ROC curves constructed for predicted values generated using a probit 
regression model and were adjusted for the ARIC Study Center where data were collected using Pepe’s method 
93, 95
. IDIs and test 
statistics were estimated only for comparisons of models m3 and m2 and models m5 and m4 using Pencina's Method 
130
. IDIs for 
comparisons of models m2 and m3 with model m1 are identical to those reported for the respective obesity risk measures in Table 4 of 
the article. 
 
R
2
 (95% CI) AUC (95% CI) IDI (p-value) R
2
 (95% CI) AUC (95% CI) IDI (p-value)
(m1)
Demographic & Geographic 
Information 3.20% 0.526 5.17% 0.604
(m2)
m1 + Simple Genetic Risk 
Assessment 3.88% 0.550 5.35% 0.607
(m3) m1 + Weighted GRS 4.88% 0.574 5.52% 0.609
1.00% 0.024 0.006 0.17% 0.002 0.001
(0.006-0.014) (0.012-0.036) (7.81E-13) (-0.001-0.005) (-0.005-0.009) (0.055)
(m4) m1 + Socioeconomic Status 4.70% 0.550 7.70% 0.643
(m5) m4 + Weighted GRS 6.20% 0.586 7.92% 0.645
1.50% 0.036 0.010 0.22% 0.002 0.002
(0.010-0.020) (0.023-0.050) (5.46E-19) (-0.001-0.006) (-0.003-0.008) (0.012)
Model
Change in predictiveness with 
addition of the weighted GRS
Change in predictiveness with 
addition of the weighted GRS
Model Components
White ARIC Participants (n=8,286) Black ARIC Participants (n=2,442)
9
3
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Supplementary Figure 2.1. Distributions of BMI Increasing Alleles for the 32 GRS SNPs and the 
Weighted Obesity Genomic Risk Score Among White and African American ARIC Participants. 
Variance of the obesity genomic risk scores (GRS) was similar among women and men within 
ethnicity (p>0.15  for both samples), but was greater among whites as compared to African 
Americans (p<0.001) according to Brown and Forsythe’s 
131
 test for equality of variances.  
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Supplementary Figure 2.2. Receiver Operating Characteristic Curves for Obesity Among 
African American ARIC Participants (n=2,442). Baseline Model = gender, age (quadratic), gender 
x age interaction, ARIC study center; Test Model = baseline model + weighted obesity genomic 
risk score. ROC Curves were constructed using predicted values from probit regressions of 
obesity (BMI≥30) on the model terms. Delta AUC (AUCTest-AUCBaseline) = 0.005, 95% CI -0.005-
0.015, p=0.30. Delta Partial AUC at 80% specificity=0, 95% CI -0.004-0.004, p=0.97. AUCs, partial 
AUCs, and delta AUCs were estimated using Pepe’s method 
93, 95
.   
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APPENDIX B 
Supplementary Materials to Chapter 3 
Supplementary Methods 
Construction of the Obesity Genetic Risk Score. We selected single nucleotide polymorphisms 
(SNPs) for investigation that were associated with an obesity-related phenotype at a threshold 
of p<1x10
-5
 in GWAS of European-descent individuals. We grouped the selected SNPs into 
“linkage disequilibrium (LD) blocks” using a linkage threshold of R
2
≥0.95 and data from the 
International HapMap Consortium’s CEU sample.
155
 We retained LD blocks that included a SNP 
associated with an obesity-related phenotype at p<1x10
-8
 in ≥1 GWAS or that included SNPs 
associated with an obesity-related phenotype at p<1x10
-5
 in ≥2 GWAS. This analysis yielded 32 
LD blocks. We selected one tag SNP from each LD block to include in the GRS. To construct the 
GRS, we weighted the obesity-associated alleles for each GRS SNP by the effect size reported for 
the SNP or its closest LD proxy in meta-analyses of BMI GWAS.
89, 90
 We then summed the 
weighted counts of obesity-associated alleles for each SNP to compute the GRS. An additive 
model was assumed on the basis of prior research documenting additive contributions to BMI 
for many of the GRS SNPs.
61, 62
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Supplemental Table 3.1. Single Nucleotide Polymorphisms Included in the Genetic Risk Score. 
Alleles are reported from the forward strand. *Nearest gene is reported for the locus identified 
in the meta-analysis of body mass index (BMI) GWAS by the GIANT Consortium.
89
 GWAS effect 
sizes are the per-allele change in BMI estimated in meta-analyses of BMI GWAS by the GIANT 
Consortium and Thorleifsson and colleagues.
90
 The following 3 SNPs failed quality controls in the 
Dunedin sample and were not included in the genetic risk score: rs11083779 near QPCTL; 
rs12641981 near GNPDA2; rs2121279 near LRP1B. 
 
Chr Nearest Gene* rs Alleles
BMI-
Increasing 
Allele
Frequency of BMI-
Increasing Allele
GWAS Effect-
Size for BMI 
NEGR1 rs2568958 A/G A 60% 0.13
TNNI3K rs1514177 C/G G 43% 0.07
PTBP2 rs11165643 C/T T 63% 0.06
SEC16B rs10913469 C/T C 21% 0.21
TMEM18 rs7567570 C/T C 82% 0.31
ADCY3, RBJ rs10182181 A/G G 51% 0.14
FANCL rs887912 A/G A 29% 0.10
CADM2 rs7640855 A/G A 20% 0.10
ETV5 rs7647305 C/T C 79% 0.12
4 SLC39A8 rs13107325 C/T T 8% 0.19
FLJ35779 rs2112347 G/T T 65% 0.10
ZNF608 rs6864049 A/G G 55% 0.07
6 TFAP2B rs2206277 A/G A 18% 0.13
LRRN6C rs1412235 C/G C 31% 0.11
LMX1B rs867559 A/G G 21% 0.24
STK33, RPL27A rs4929949 C/T C 52% 0.06
BDNF rs6265 A/G G 52% 0.18
MTCH2 rs10838738 A/G G 34% 0.05
12 BCDIN3, FAIM2 rs7138803 A/G A 36% 0.12
13 MTIF3 rs1475219 C/T C 20% 0.09
PRKD1 rs11847697 C/T T 3% 0.17
NRXN3 rs10150332 C/T C 23% 0.13
15 MAP2K5 rs2241423 A/G G 78% 0.13
GPRC5B rs12446554 G/T G 87% 0.17
SH2B1 rs4788102 A/G A 39% 0.15
FTO rs9939609 A/T A 36% 0.38
18 MC4R rs921971 C/T C 28% 0.21
KCTD15 rs29941 C/T C 67% 0.06
ZC3H4, TMEM160 rs3810291 A/G A 68% 0.09
3
2
1
19
16
14
11
9
5
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Supplemental Table 3.2. The Genetic Risk Score and the Family History Score have 
Independent Effects on Growth and Obesity Risk. Panel A presents bivariate effect sizes for the 
genetic risk score and the family history score from the life course growth model and obesity 
prediction models. Panel B presents the independent effects of the genetic risk score and the 
family history score on life course growth and obesity risk. Independent effects were estimated 
from multivariate growth models (life course growth) and multivariate Poisson regression 
models (obesity). The genetic risk score and the family history score were standardized to have 
means of 0 and standard deviations of 1 for analyses. All analyses were adjusted for sex. 
 
Model 
Intercept
Childhood 
Slope
Adulthood 
Slope Teens 20s 30s Chronic
Panel A. Bivariate Associations
Genome Risk Score 0.38 0.03 0.02 1.42 1.37 1.23 1.37
p<0.001 p<0.001 p=0.014 (1.10, 1.83) (1.13, 1.67) (1.08, 1.39) (1.09, 1.73)
Family History Score 0.63 0.05 0.04 1.63 1.72 1.49 1.83
p<0.001 p<0.001 p<0.001 (1.36, 1.95) (1.51, 1.97) (1.35, 1.63) (1.58, 2.13)
Panel B. Independent Associations
Genome Risk Score 0.31 0.02 0.01 1.31 1.27 1.17 1.26
p<0.001 p=0.004 p=0.065 (1.01, 1.70) (1.04, 1.55) (1.03, 1.32) (1.00, 1.59)
Family History Score 0.60 0.05 0.04 1.58 1.67 1.46 1.78
p<0.001 p<0.001 p<0.001 (1.31, 1.90) (1.46, 1.92) (1.32, 1.61) (1.52, 2.09)
Beta/ p-value Relative Risk (95% Confidence Interval)
ObesityLife Course Growth
Beta/ p-value Relative Risk (95% Confidence Interval)
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Supplemental Table 3.3. Indirect effects of the genetic risk score on adult obesity outcomes 
mediated through birth-3 weight gain and the adiposity rebound. Indirect effects were 
estimated using the structural equation described by MacKinnon & Dwyer
140
 implemented with 
Poisson regression models. Indirect effect estimates were exponentiated to compute risk ratios. 
Indirect effect estimates for the adiposity rebound reflect the combined indirect effects of age 
and BMI at adiposity rebound. Analyses were adjusted for sex. Confidence intervals were 
estimated from 5000 bootstrap repetitions.  
 
 
  
Developmental Phenotype
Birth-3 Weight Gain 1.06 (1.01, 1.12) 1.03 (1.00, 1.06) 1.01 (0.99, 1.04) 1.04 (1.01, 1.08)
Adiposity Rebound 1.32 (1.17, 1.52) 1.19 (1.11, 1.31) 1.12 (1.06, 1.19) 1.20 (1.11, 1.32)
Indirect Effect Expressed as a Relative Risk  (95% Confidence Intervals)
Chronic30s20sTeens
Obesity Outcome
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Supplemental Figure 3.1. Distribution of the Genetic Risk Score. The transparent bars show the 
distribution of the count of risk alleles across the 29 SNPs included in the genetic risk score (i.e. 
before weights were applied). The kernel density plot shows the distribution of the weighted 
genetic risk score.  
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APPENDIX C 
Supplementary Materials to Chapter 4 
Supplemental Table 4.1. Single nucleotide polymorphisms (SNPs) included in the genetic risk score. 
Effect allele frequencies for the GWAS SNPs are based on the HapMap CEU sample (release 22 for SNPs 
rs12595538, rs8032771, and rs4105144; version 3 release 2 for SNPs rs16969968 and rs6495308). 
Linkage disequilibrium (LD) was obtained from 1000 Genomes project data for all SNPs except 
rs4105144. LD between this SNP and rs8102683 was obtained using HapMap Release 22 data. All allele 
frequency and linkage queries were run through the Broad Institute’s SNAP tool 
(http://www.broadinstitute.org/mpg/snap/ldsearch.php). Effect allele frequencies for the SNPs 
genotyped in the Dunedin sample are based on n=880 European-descent study members.  
 
 
 
Chr Genes GWAS SNP Alleles
Effect 
Allele
Freq. 
(HapMap)
Dunedin 
SNP
LD with 
GWAS SNP Alleles
Effect 
Allele
Freq. 
(Dunedin)
rs16969968 A/G A 39% rs10519203 0.93 A/G G 34%
rs6495308 C/T T 80% rs4887069 1.00 A/G A 79%
rs12595538 A/T A 62% rs7164529 0.90 A/G G 61%
rs8032771 A/G A 52% rs11072810 0.97 C/T T 50%
EGLN2 rs7937 C/T T 55% rs7937 1.00 C/T T 57%
CYP2A6 rs4105144 A/G G 74% rs8102683 0.87 C/T C 73%
15
19
CHRNA5, CHRNA3, 
CHRNB4
ADAMTS7, 
MORF4L1
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Supplemental Table 4.2. Associations between genetic risk and clinical phenotypes of smoking 
behavior are mediated by developmental phenotypes of rapid progression from smoking initiation to 
heavy smoking. Indirect, direct, and total effects were estimated from the structural equation described 
by MacKinnon and Dwyer implemented using the methods described by Preacher and colleagues.
140, 142, 
143
 Percentile-based 95% confidence intervals were estimated from 1,000 bootstrap repetitions. 
Developmental phenotypes were early conversion to daily smoking (by age 15 years) and rapid 
progression to heavy smoking (by age 18 years). Both developmental phenotypes were associated with 
the latent adult smoking problems factor and with the individual clinical phenotypes (p<0.001 for all). 
Collectively, early conversion to daily smoking and rapid progression to heavy smoking explained 23% of 
the variance in the latent smoking problems factor.   
Total Effect of                             
Genetic Risk
Direct (un-mediated)                 
Effect of Genetic Risk
Indirect Effect of Genetic Risk 
Mediated Through 
Developmental Phenotypes
Proportion of Total Effect 
Accounted for by the Indirect 
Effect
B /[95% CI] / p-value B /[95% CI] / p-value B /[95% CI] / p-value %
Latent Adult Smoking Problems Factor
0.15 0.03 0.12 81%
[0.05-0.26] [-0.04-0.10] [0.05-0.20]
p=4.33E-03 p=4.02E-01 p=1.79E-03
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